mutations O
of O
the O
atm O
gene O
detected O
in O
japanese O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
patients O
: O
possible O
preponderance O
of O
the O
two O
founder O
mutations O
4612del165 O
and O
7883del5 O
. O

3 O
has O
recently O
been O
identified O
as O
the O
gene O
responsible O
for O
the O
human O
recessive B-Disease
disease I-Disease
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
. O

in O
order O
to O
define O
the O
types O
of O
disease O
- O
causing O
atm O
mutations O
in O
japanese O
a B-Disease
- I-Disease
t I-Disease
patients O
as O
well O
as O
to O
look O
for O
possible O
mutational O
hotspots O
, O
reverse O
- O
transcribed O
rna O
derived O
from O
ten O
patients O
belonging O
to O
eight O
unrelated O
japanese O
a B-Disease
- I-Disease
t I-Disease
families O
was O
analyzed O
for O
mutations O
by O
the O
restriction O
endonuclease O
fingerprinting O
method O
. O

w474c O
amino O
acid O
substitution O
affects O
early O
processing O
of O
the O
alpha O
- O
subunit O
of O
beta O
- O
hexosaminidase O
a O
and O
is O
associated O
with O
subacute O
g B-Disease
( I-Disease
m2 I-Disease
) I-Disease
gangliosidosis I-Disease
. O

mutations O
in O
the O
hexa O
gene O
, O
encoding O
the O
alpha O
- O
subunit O
of O
beta O
- O
hexosaminidase O
a O
( O
hex O
a O
) O
, O
that O
abolish O
hex O
a O
enzyme O
activity O
cause O
tay B-Disease
- I-Disease
sachs I-Disease
disease I-Disease
( O
tsd B-Disease
) O
, O
the O
fatal O
infantile B-Disease
form I-Disease
of I-Disease
g I-Disease
( I-Disease
m2 I-Disease
) I-Disease
gangliosidosis I-Disease
, I-Disease
type I-Disease
1 I-Disease
. O

we O
identified O
a O
1422 O
g O
- O
- O
> O
c O
( O
amino O
acid O
w474c O
) O
substitution O
in O
the O
first O
position O
of O
exon O
13 O
of O
hexa O
of O
a O
non O
- O
jewish O
proband O
who O
manifested O
a O
subacute O
variant O
of O
g B-Disease
( I-Disease
m2 I-Disease
) I-Disease
gangliosidosis I-Disease
. O

when O
the O
w474c O
- O
containing O
alpha O
- O
subunit O
was O
transiently O
co O
- O
expressed O
with O
the O
beta O
- O
subunit O
to O
produce O
hex O
a O
( O
alphabeta O
) O
in O
cos O
- O
7 O
cells O
, O
the O
mature O
alpha O
- O
subunit O
was O
present O
, O
but O
its O
level O
was O
much O
lower O
than O
that O
from O
normal O
alpha O
- O
subunit O
transfections O
, O
although O
higher O
than O
in O
those O
cells O
transfected O
with O
an O
alpha O
- O
subunit O
associated O
with O
infantile O
tsd B-Disease
. O

we O
conclude O
that O
the O
1422 O
g O
- O
- O
> O
c O
mutation O
is O
the O
cause O
of O
hex B-Disease
a I-Disease
enzyme I-Disease
deficiency I-Disease
in O
the O
proband O
. O

the O
resulting O
w474c O
substitution O
clearly O
interferes O
with O
alpha O
- O
subunit O
processing O
, O
but O
because O
the O
base O
substitution O
falls O
at O
the O
first O
position O
of O
exon O
13 O
, O
aberrant O
splicing O
may O
also O
contribute O
to O
hex B-Disease
a I-Disease
deficiency I-Disease
in O
this O
proband O
. O

. O

two O
frequent O
missense O
mutations O
in O
pendred B-Disease
syndrome I-Disease
. O

pendred B-Disease
syndrome I-Disease
is O
an O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
characterized O
by O
early O
childhood O
deafness B-Disease
and O
goiter B-Disease
. O

we O
performed O
mutation O
analysis O
of O
the O
pds B-Disease
gene O
in O
patients O
from O
14 O
pendred B-Disease
families O
originating O
from O
seven O
countries O
and O
identified O
all O
mutations O
. O

pendred B-Disease
patients O
in O
three O
non O
- O
consanguineous O
families O
were O
shown O
to O
be O
compound O
heterozygotes O
for O
l236p O
and O
t416p O
. O

the O
identification O
of O
two O
frequent O
pds B-Disease
mutations O
will O
facilitate O
the O
molecular O
diagnosis O
of O
pendred B-Disease
syndrome I-Disease
. O

insertional O
mutation O
by O
transposable O
element O
, O
l1 O
, O
in O
the O
dmd B-Disease
gene O
results O
in O
x B-Disease
- I-Disease
linked I-Disease
dilated I-Disease
cardiomyopathy I-Disease
. O

x B-Disease
- I-Disease
linked I-Disease
dilated I-Disease
cardiomyopathy I-Disease
( O
xldcm B-Disease
) O
is O
a O
clinical O
phenotype O
of O
dystrophinopathy B-Disease
which O
is O
characterized O
by O
preferential O
myocardial B-Disease
involvement I-Disease
without O
any O
overt O
clinical O
signs O
of O
skeletal B-Disease
myopathy I-Disease
. O

to O
date O
, O
several O
mutations O
in O
the O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
gene O
, O
dmd O
, O
have O
been O
identified O
in O
patients O
with O
xldcm B-Disease
, O
but O
a O
pathogenic O
correlation O
of O
these O
cardiospecific O
mutations O
in O
dmd O
with O
the O
xldcm B-Disease
phenotype O
has O
remained O
to O
be O
elucidated O
. O

we O
report O
here O
the O
identification O
of O
a O
unique O
de O
novo O
l1 O
insertion O
in O
the O
muscle O
exon O
1 O
in O
dmd O
in O
three O
xldcm B-Disease
patients O
from O
two O
unrelated O
japanese O
families O
. O

we O
speculate O
that O
this O
insertion O
of O
an O
l1 O
sequence O
in O
dmd O
is O
responsible O
for O
some O
of O
the O
population O
of O
japanese O
patients O
with O
xldcm B-Disease
. O

. O

severe O
early O
- O
onset O
obesity B-Disease
, O
adrenal B-Disease
insufficiency I-Disease
and O
red O
hair O
pigmentation O
caused O
by O
pomc O
mutations O
in O
humans O
. O

while O
a O
few O
cases O
of O
isolated O
acth B-Disease
deficiency I-Disease
have O
been O
reported O
( O
omim O
201400 O
) O
, O
an O
inherited O
pomc O
defect O
has O
not O
been O
described O
so O
far O
. O

recent O
studies O
in O
animal O
models O
elucidated O
a O
central O
role O
of O
alpha O
- O
msh O
in O
the O
regulation O
of O
food O
intake O
by O
activation O
of O
the O
brain O
melanocortin O
- O
4 O
- O
receptor O
( O
mc4 O
- O
r O
; O
refs O
3 O
- O
5 O
) O
and O
the O
linkage O
of O
human O
obesity B-Disease
to O
chromosome O
2 O
in O
close O
proximity O
to O
the O
pomc O
locus O
, O
led O
to O
the O
proposal O
of O
an O
association O
of O
pomc O
with O
human O
obesity B-Disease
. O

the O
dual O
role O
of O
alpha O
- O
msh O
in O
regulating O
food O
intake O
and O
influencing O
hair O
pigmentation O
predicts O
that O
the O
phenotype O
associated O
with O
a O
defect O
in O
pomc O
function O
would O
include O
obesity B-Disease
, O
alteration O
in O
pigmentation O
and O
acth B-Disease
deficiency I-Disease
. O

these O
findings O
represent O
the O
first O
examples O
of O
a O
genetic B-Disease
defect I-Disease
within O
the O
pomc O
gene O
and O
define O
a O
new O
monogenic B-Disease
endocrine I-Disease
disorder I-Disease
resulting O
in O
early O
- O
onset O
obesity B-Disease
, O
adrenal B-Disease
insufficiency I-Disease
and O
red O
hair O
pigmentation O
. O

. O

a O
european O
multicenter O
study O
of O
phenylalanine B-Disease
hydroxylase I-Disease
deficiency I-Disease
: O
classification O
of O
105 O
mutations O
and O
a O
general O
system O
for O
genotype O
- O
based O
prediction O
of O
metabolic O
phenotype O
. O

phenylketonuria B-Disease
( O
pku B-Disease
) O
and O
mild B-Disease
hyperphenylalaninemia I-Disease
( O
mhp B-Disease
) O
are O
allelic B-Disease
disorders I-Disease
caused O
by O
mutations O
in O
the O
gene O
encoding O
phenylalanine O
hydroxylase O
( O
pah O
) O
. O

previous O
studies O
have O
suggested O
that O
the O
highly O
variable O
metabolic O
phenotypes O
of O
pah B-Disease
deficiency I-Disease
correlate O
with O
pah O
genotypes O
. O

our O
data O
indicate O
that O
the O
pah O
- O
mutation O
genotype O
is O
the O
main O
determinant O
of O
metabolic O
phenotype O
in O
most O
patients O
with O
pah B-Disease
deficiency I-Disease
. O

in O
the O
present O
study O
, O
the O
classification O
of O
105 O
pah O
mutations O
may O
allow O
the O
prediction O
of O
the O
biochemical O
phenotype O
in O
> O
10 O
, O
0 O
genotypes O
, O
which O
may O
be O
useful O
for O
the O
management O
of O
hyperphenylalaninemia B-Disease
in O
newborns O
. O

somatic O
instability O
of O
the O
ctg O
repeat O
in O
mice O
transgenic O
for O
the O
myotonic B-Disease
dystrophy I-Disease
region O
is O
age O
dependent O
but O
not O
correlated O
to O
the O
relative O
intertissue O
transcription O
levels O
and O
proliferative O
capacities O
. O

a O
( O
ctg O
) O
nexpansion O
in O
the O
3 O
- O
untranslated O
region O
( O
utr O
) O
of O
the O
dm O
protein O
kinase O
gene O
( O
dmpk O
) O
is O
responsible O
for O
causing O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
. O

the O
trinucleotide O
repeat O
instability O
mechanisms O
involved O
in O
dm B-Disease
and O
other O
human O
genetic B-Disease
diseases I-Disease
are O
unknown O
. O

we O
studied O
somatic O
instability O
by O
measuring O
the O
ctg O
repeat O
length O
at O
several O
ages O
in O
various O
tissues O
of O
transgenic O
mice O
carrying O
a O
( O
ctg O
) O
55expansion O
surrounded O
by O
45 O
kb O
of O
the O
human O
dm B-Disease
region O
, O
using O
small O
- O
pool O
pcr O
. O

as O
observed O
in O
some O
of O
the O
tissues O
of O
dm B-Disease
patients O
, O
there O
is O
a O
tendency O
for O
repeat O
length O
and O
somatic O
mosaicism O
to O
increase O
with O
the O
age O
of O
the O
mouse O
. O

a O
novel O
missense O
mutation O
in O
patients O
from O
a O
retinoblastoma B-Disease
pedigree O
showing O
only O
mild O
expression O
of O
the O
tumor B-Disease
phenotype O
. O

we O
have O
used O
single O
strand O
conformation O
polymorphism O
analysis O
to O
study O
the O
27 O
exons O
of O
the O
rb1 O
gene O
in O
individuals O
from O
a O
family O
showing O
mild O
expression O
of O
the O
retinoblastoma B-Disease
phenotype O
. O

in O
this O
family O
affected O
individuals O
developed O
unilateral B-Disease
tumors I-Disease
and O
, O
as O
a O
result O
of O
linkage O
analysis O
, O
unaffected O
mutation O
carriers O
were O
also O
identified O
within O
the O
pedigree O
. O

analysis O
of O
all O
family O
members O
demonstrated O
that O
the O
missense O
mutation O
co O
- O
segregated O
with O
patients O
with O
tumors B-Disease
or O
who O
, O
as O
a O
result O
of O
linkage O
analysis O
had O
been O
predicted O
to O
carry O
the O
predisposing O
mutation O
. O

maternal B-Disease
disomy I-Disease
and O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
consistent O
with O
gamete O
complementation O
in O
a O
case O
of O
familial O
translocation O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O

2 O
) O
. O

maternal B-Disease
uniparental I-Disease
disomy I-Disease
( I-Disease
upd I-Disease
) I-Disease
for I-Disease
chromosome I-Disease
15 I-Disease
is O
responsible O
for O
an O
estimated O
30 O
% O
of O
cases O
of O
prader B-Disease
- I-Disease
willi I-Disease
syndrome I-Disease
( O
pws B-Disease
) O
. O

we O
report O
on O
an O
unusual O
case O
of O
maternal B-Disease
disomy I-Disease
15 I-Disease
in O
pws B-Disease
that O
is O
most O
consistent O
with O
adjacent O
- O
1 O
segregation O
of O
a O
paternal O
t O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O

2 O
) O
with O
simultaneous O
maternal O
meiotic O
nondisjunction O
for O
chromosome O
15 O
. O

the O
patient O
( O
j O
. O

b O
. O

) O
, O
a O
17 O
- O
year O
- O
old O
white O
male O
with O
pws B-Disease
, O
was O
found O
to O
have O
47 O
chromosomes O
with O
a O
supernumerary O
, O
paternal O
der O
( O
15 O
) O
consisting O
of O
the O
short O
arm O
and O
the O
proximal O
long O
arm O
of O
chromosome O
15 O
, O
and O
distal O
chromosome O
arm O
3p O
. O

fluorescent O
in O
situ O
hybridization O
analysis O
demonstrated O
that O
the O
pws B-Disease
critical O
region O
resided O
on O
the O
derivative O
chromosome O
3 O
and O
that O
there O
was O
no O
deletion O
of O
the O
pws B-Disease
region O
on O
the O
normal O
pair O
of O
15s O
present O
in O
j O
. O

maternal B-Disease
disomy I-Disease
was O
confirmed O
by O
polymerase O
chain O
reaction O
analysis O
of O
microsatellite O
repeats O
at O
the O
gamma O
- O
aminobutyric O
acid O
receptor O
beta3 O
subunit O
( O
gabrb3 O
) O
locus O
. O

uniparental B-Disease
disomy I-Disease
associated O
with O
unbalanced O
segregation O
of O
non O
- O
robertsonian O
translocations O
has O
been O
reported O
previously O
but O
has O
not O
, O
to O
our O
knowledge O
, O
been O
observed O
in O
a O
case O
of O
pws B-Disease
. O

furthermore O
, O
our O
findings O
are O
best O
interpreted O
as O
TRUE O
gamete O
complementation O
resulting O
in O
maternal B-Disease
upd I-Disease
15 I-Disease
and O
pws B-Disease
schwartz B-Disease
- I-Disease
jampel I-Disease
syndrome I-Disease
type I-Disease
2 I-Disease
and O
stuve B-Disease
- I-Disease
wiedemann I-Disease
syndrome I-Disease
: O
a O
case O
for O
lumping O
. O

recent O
studies O
demonstrated O
the O
existence O
of O
a O
genetically O
distinct O
, O
usually O
lethal O
form O
of O
the O
schwartz B-Disease
- I-Disease
jampel I-Disease
syndrome I-Disease
( O
sjs B-Disease
) O
of O
myotonia B-Disease
and O
skeletal B-Disease
dysplasia I-Disease
, O
which O
we O
called O
sjs B-Disease
type I-Disease
2 I-Disease
. O

this O
disorder O
is O
reminiscent O
of O
another O
rare O
condition O
, O
the O
stuve B-Disease
- I-Disease
wiedemann I-Disease
syndrome I-Disease
( O
sws B-Disease
) O
, O
which O
comprises O
campomelia B-Disease
at O
birth O
with O
skeletal B-Disease
dysplasia I-Disease
, O
contractures B-Disease
, O
and O
early B-Disease
death I-Disease
. O

to O
test O
for O
possible O
nosologic O
identity O
between O
these O
disorders O
, O
we O
reviewed O
the O
literature O
and O
obtained O
a O
follow O
- O
up O
of O
the O
only O
two O
surviving O
patients O
, O
one O
with O
sjs B-Disease
type I-Disease
2 I-Disease
at O
age O
10 O
years O
and O
another O
with O
sws B-Disease
at O
age O
7 O
years O
. O

patients O
reported O
as O
having O
either O
neonatal O
sjs B-Disease
or O
sws B-Disease
presented O
a O
combination O
of O
a O
severe O
, O
prenatal O
- O
onset O
neuromuscular B-Disease
disorder I-Disease
( O
with O
congenital B-Disease
joint I-Disease
contractures I-Disease
, O
respiratory O
and O
feeding O
difficulties O
, O
tendency O
to O
hyperthermia B-Disease
, O
and O
frequent O
death O
in O
infancy O
) O
with O
a O
distinct O
campomelic B-Disease
- I-Disease
metaphyseal I-Disease
skeletal I-Disease
dysplasia I-Disease
. O

the O
follow O
- O
up O
observation O
of O
an O
identical O
and O
unique O
pattern O
of O
progressive O
bone B-Disease
dysplasia I-Disease
in O
the O
two O
patients O
( O
one O
with O
sjs B-Disease
type I-Disease
2 I-Disease
, O
one O
with O
sws B-Disease
) O
surviving O
beyond O
infancy O
adds O
to O
the O
evidence O
in O
favor O
of O
identity O
. O

the O
hypothesis O
that O
sws B-Disease
and O
sjs B-Disease
type I-Disease
2 I-Disease
are O
the O
same O
disorder O
should O
be O
testable O
by O
molecular O
methods O
. O

. O

a O
mouse O
model O
of O
severe O
von B-Disease
willebrand I-Disease
disease I-Disease
: O
defects O
in O
hemostasis O
and O
thrombosis B-Disease
. O

von B-Disease
willebrand I-Disease
factor I-Disease
( I-Disease
vwf I-Disease
) I-Disease
deficiency I-Disease
causes O
severe O
von B-Disease
willebrand I-Disease
disease I-Disease
in O
humans O
. O

vwf B-Disease
- I-Disease
deficient I-Disease
mice O
appeared O
normal O
at O
birth O
; O
they O
were O
viable O
and O
fertile O
. O

neither O
vwf O
nor O
vwf O
propolypeptide O
( O
von B-Disease
willebrand I-Disease
antigen O
ii O
) O
were O
detectable O
in O
plasma O
, O
platelets O
, O
or O
endothelial O
cells O
of O
the O
homozygous O
mutant O
mice O
. O

defective O
thrombosis B-Disease
in O
mutant O
mice O
was O
also O
evident O
in O
an O
in O
vivo O
model O
of O
vascular B-Disease
injury I-Disease
. O

we O
conclude O
that O
these O
mice O
very O
closely O
mimic O
severe O
human O
von B-Disease
willebrand I-Disease
disease I-Disease
and O
will O
be O
very O
useful O
for O
investigating O
the O
role O
of O
vwf O
in O
normal O
physiology O
and O
in O
disease O
models O
. O

. O

oral O
contraceptives O
and O
the O
risk O
of O
hereditary B-Disease
ovarian I-Disease
cancer I-Disease
. O

hereditary B-Disease
ovarian I-Disease
cancer I-Disease
clinical O
study O
group O
. O

background O
women O
with O
mutations O
in O
either O
the O
brca1 O
or O
the O
brca2 O
gene O
have O
a O
high O
lifetime O
risk O
of O
ovarian B-Disease
cancer I-Disease
. O

oral O
contraceptives O
protect O
against O
ovarian B-Disease
cancer I-Disease
in O
general O
, O
but O
it O
is O
not O
known O
whether O
they O
also O
protect O
against O
hereditary B-Disease
forms I-Disease
of I-Disease
ovarian I-Disease
cancer I-Disease
. O

methods O
we O
enrolled O
207 O
women O
with O
hereditary B-Disease
ovarian I-Disease
cancer I-Disease
and O
161 O
of O
their O
sisters O
as O
controls O
in O
a O
case O
- O
control O
study O
. O

results O
the O
adjusted O
odds O
ratio O
for O
ovarian B-Disease
cancer I-Disease
associated O
with O
any O
past O
use O
of O
oral O
contraceptives O
was O
0 O
. O

oral O
- O
contraceptive O
use O
protected O
against O
ovarian B-Disease
cancer I-Disease
both O
for O
carriers O
of O
the O
brca1 O
mutation O
( O
odds O
ratio O
, O
0 O
. O

5 O
; O
95 O
percent O
confidence O
interval O
, O
0 O
. O

3 O
to O
0 O
. O

9 O
) O
and O
for O
carriers O
of O
the O
brca2 O
mutation O
( O
odds O
ratio O
, O
0 O
. O

4 O
; O
95 O
percent O
confidence O
interval O
, O
0 O
. O

2 O
to O
1 O
. O

1 O
) O
. O

conclusions O
oral O
- O
contraceptive O
use O
may O
reduce O
the O
risk O
of O
ovarian B-Disease
cancer I-Disease
in O
women O
with O
pathogenic O
mutations O
in O
the O
brca1 O
or O
brca2 O
gene O
a O
japanese O
family O
with O
adrenoleukodystrophy B-Disease
with O
a O
codon O
291 O
deletion O
: O
a O
clinical O
, O
biochemical O
, O
pathological O
, O
and O
genetic O
report O
. O

we O
report O
a O
japanese O
family O
with O
adrenoleukodystrophy B-Disease
( O
ald B-Disease
) O
with O
a O
three O
base O
pair O
deletion O
( O
delgag O
291 O
) O
in O
the O
ald B-Disease
gene O
. O

while O
the O
proband O
( O
patient O
1 O
) O
was O
classified O
as O
having O
a O
rare O
intermediate O
type O
of O
adult O
cerebral O
and O
cerebello O
- O
brain O
stem O
forms O
, O
his O
younger O
brother O
( O
patient O
2 O
) O
and O
nephew O
( O
patient O
3 O
) O
had O
a O
childhood O
ald B-Disease
type O
. O

the O
tau O
level O
in O
the O
cerebrospinal O
fluid O
( O
csf O
) O
in O
patient O
1 O
was O
as O
high O
as O
that O
of O
patients O
with O
alzheimers B-Disease
disease I-Disease
( O
ad B-Disease
) O
. O

his O
brain O
magnetic O
resonance O
image O
( O
mri O
) O
showed O
abnormalities B-Disease
in I-Disease
the I-Disease
bilateral I-Disease
cerebellar I-Disease
hemispheres I-Disease
and O
brain O
stem O
, O
but O
not O
in O
the O
cerebral O
white O
matter O
, O
where O
marked O
reductions O
of O
the O
cerebral O
blood O
flow O
and O
oxygen O
metabolism O
were O
clearly O
demonstrated O
by O
positron O
emission O
tomography O
( O
pet O
) O
. O

in O
patients O
2 O
and O
3 O
, O
the O
autopsy O
findings O
showed O
massive O
demyelination B-Disease
of I-Disease
the I-Disease
cerebral I-Disease
white I-Disease
matter I-Disease
with O
sparing O
of O
the O
u O
- O
fibers O
, O
compatible O
with O
the O
findings O
of O
childhood O
ald B-Disease
. O

the O
findings O
in O
this O
family O
suggest O
that O
delgag291 O
is O
part O
of O
the O
cause O
of O
japanese O
ald B-Disease
with O
phenotypic O
variations O
. O

moreover O
, O
although O
the O
scale O
of O
the O
study O
is O
limited O
, O
there O
is O
a O
possibility O
that O
pet O
can O
detect O
an O
insidious B-Disease
lesion I-Disease
which O
is O
undetectable O
by O
computed O
tomogram O
( O
ct O
) O
or O
mri O
analysis O
, O
and O
that O
the O
higher O
level O
of O
tau O
reflects O
the O
process O
of O
neuronal B-Disease
degeneration I-Disease
in O
ald B-Disease
. O

nonsense O
mutation O
in O
exon O
4 O
of O
human O
complement O
c9 O
gene O
is O
the O
major O
cause O
of O
japanese O
complement B-Disease
c9 I-Disease
deficiency I-Disease
. O

deficiency B-Disease
of I-Disease
the I-Disease
ninth I-Disease
component I-Disease
of I-Disease
human I-Disease
complement I-Disease
( O
c9 O
) O
is O
the O
most O
common O
complement B-Disease
deficiency I-Disease
in O
japan O
but O
is O
rare O
in O
other O
countries O
. O

we O
studied O
the O
molecular O
basis O
of O
c9 B-Disease
deficiency I-Disease
in O
four O
japanese O
c9 B-Disease
- I-Disease
deficient I-Disease
patients O
who O
had O
suffered O
from O
meningococcal B-Disease
meningitis I-Disease
. O

direct O
sequencing O
of O
amplified O
c9 O
cdna O
and O
dna O
revealed O
a O
nonsense O
substitution O
( O
cga O
- O
- O
> O
tga O
) O
at O
codon O
95 O
in O
exon O
4 O
in O
the O
four O
c9 B-Disease
- I-Disease
deficient I-Disease
individuals O
. O

the O
common O
mutation O
at O
codon O
95 O
in O
exon O
4 O
might O
be O
responsible O
for O
most O
japanese O
c9 B-Disease
deficiency I-Disease
. O

. O

the O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
susceptibility O
gene O
brca1 O
encodes O
a O
zinc O
finger O
protein O
of O
unknown O
function O
. O

here O
, O
it O
is O
shown O
that O
mouse O
embryonic O
stem O
cells O
deficient B-Disease
in I-Disease
brca1 I-Disease
are O
defective O
in O
the O
ability O
to O
carry O
out O
transcription O
- O
coupled O
repair O
of O
oxidative O
dna O
damage O
, O
and O
are O
hypersensitive O
to O
ionizing O
radiation O
and O
hydrogen O
peroxide O
. O

heterozygous O
mutations O
in O
the O
human O
pax6 O
gene O
result O
in O
various O
phenotypes O
, O
including O
aniridia B-Disease
, O
peters B-Disease
anomaly I-Disease
, O
autosomal B-Disease
dominant I-Disease
keratitis I-Disease
, O
and O
familial B-Disease
foveal I-Disease
dysplasia I-Disease
. O

it O
is O
believed O
that O
the O
mutated O
allele O
of O
pax6 O
produces O
an O
inactive O
protein O
and O
aniridia B-Disease
is O
caused O
due O
to O
genetic O
haploinsufficiency O
. O

however O
, O
several O
truncation O
mutations O
have O
been O
found O
to O
occur O
in O
the O
c O
- O
terminal O
half O
of O
pax6 O
in O
patients O
with O
aniridia B-Disease
resulting O
in O
mutant O
proteins O
that O
retain O
the O
dna O
- O
binding O
domains O
but O
have O
lost O
most O
of O
the O
transactivation O
domain O
. O

these O
results O
provide O
a O
new O
insight O
into O
the O
role O
of O
mutant O
pax6 O
in O
causing O
aniridia B-Disease
. O

. O

reversal O
of O
severe O
hypertrophic B-Disease
cardiomyopathy I-Disease
and O
excellent O
neuropsychologic O
outcome O
in O
very B-Disease
- I-Disease
long I-Disease
- I-Disease
chain I-Disease
acyl I-Disease
- I-Disease
coenzyme I-Disease
a I-Disease
dehydrogenase I-Disease
deficiency I-Disease
. O

very B-Disease
- I-Disease
long I-Disease
- I-Disease
chain I-Disease
acyl I-Disease
- I-Disease
coenzyme I-Disease
a I-Disease
dehydrogenase I-Disease
( I-Disease
vlcad I-Disease
) I-Disease
deficiency I-Disease
is O
a O
disorder O
of O
fatty O
acid O
beta O
oxidation O
that O
reportedly O
has O
high O
rates O
of O
morbidity O
and O
mortality O
. O

we O
describe O
the O
outcome O
of O
a O
5 O
- O
year O
- O
old O
girl O
with O
vlcad B-Disease
deficiency I-Disease
who O
was O
first O
seen O
at O
5 O
months O
of O
age O
with O
severe O
hypertrophic B-Disease
cardiomyopathy I-Disease
, O
hepatomegaly B-Disease
, O
encephalopathy B-Disease
, O
and O
hypotonia B-Disease
. O

biochemical O
studies O
indicated O
vlcad B-Disease
deficiency I-Disease
caused O
by O
a O
stable O
yet O
inactive O
enzyme O
. O

clinical O
recognition O
of O
vlcad B-Disease
deficiency I-Disease
is O
important O
because O
it O
is O
one O
of O
the O
few O
directly O
treatable O
causes O
of O
cardiomyopathy B-Disease
in O
children O
. O

. O

a O
gene O
encoding O
a O
novel O
transmembrane O
protein O
was O
identified O
by O
dna O
sequence O
analysis O
within O
the O
insulin B-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
mellitus I-Disease
( O
iddm B-Disease
) O
locus O
iddm4 O
on O
chromosome O
11q13 O
. O

based O
on O
its O
chromosomal O
position O
, O
this O
gene O
is O
a O
candidate O
for O
conferring O
susceptibility O
to O
diabetes B-Disease
. O

the O
apc B-Disease
variants O
i1307k O
and O
e1317q O
are O
associated O
with O
colorectal B-Disease
tumors I-Disease
, O
but O
not O
always O
with O
a O
family O
history O
. O

classical O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
is O
a O
high O
- O
penetrance O
autosomal B-Disease
dominant I-Disease
disease I-Disease
that O
predisposes O
to O
hundreds O
or O
thousands O
of O
colorectal B-Disease
adenomas I-Disease
and I-Disease
carcinoma I-Disease
and O
that O
results O
from O
truncating O
mutations O
in O
the O
apc B-Disease
gene O
. O

a O
variant O
of O
fap B-Disease
is O
attenuated B-Disease
adenomatous I-Disease
polyposis I-Disease
coli I-Disease
, O
which O
results O
from O
germ O
- O
line O
mutations O
in O
the O
5 O
and O
3 O
regions O
of O
the O
apc B-Disease
gene O
. O

attenuated B-Disease
adenomatous I-Disease
polyposis I-Disease
coli I-Disease
patients O
have O
multiple O
colorectal B-Disease
adenomas I-Disease
( O
typically O
fewer O
than O
100 O
) O
without O
the O
florid O
phenotype O
of O
classical O
fap B-Disease
. O

another O
group O
of O
patients O
with O
multiple O
adenomas B-Disease
has O
no O
mutations O
in O
the O
apc B-Disease
gene O
, O
and O
their O
phenotype O
probably O
results O
from O
variation O
at O
a O
locus O
, O
or O
loci O
, O
elsewhere O
in O
the O
genome O
. O

recently O
, O
however O
, O
a O
missense O
variant O
of O
apc B-Disease
( O
i1307k O
) O
was O
described O
that O
confers O
an O
increased O
risk O
of O
colorectal B-Disease
tumors I-Disease
, O
including O
multiple O
adenomas B-Disease
, O
in O
ashkenazim O
. O

we O
have O
studied O
a O
set O
of O
164 O
patients O
with O
multiple O
colorectal B-Disease
adenomas I-Disease
and I-Disease
/ I-Disease
or I-Disease
carcinoma I-Disease
and O
analyzed O
codons O
1263 O
- O
1377 O
( O
exon O
15g O
) O
of O
the O
apc B-Disease
gene O
for O
germ O
- O
line O
variants O
. O

four O
patients O
had O
a O
germ O
- O
line O
e1317q O
missense O
variant O
of O
apc O
that O
was O
not O
present O
in O
controls O
; O
one O
of O
these O
individuals O
had O
an O
unusually O
large O
number O
of O
metaplastic B-Disease
polyps I-Disease
of I-Disease
the I-Disease
colorectum I-Disease
. O

there O
is O
increasing O
evidence O
that O
there O
exist O
germ O
- O
line O
variants O
of O
the O
apc B-Disease
gene O
that O
predispose O
to O
the O
development O
of O
multiple O
colorectal B-Disease
adenomas I-Disease
and I-Disease
carcinoma I-Disease
, O
but O
without O
the O
florid O
phenotype O
of O
classical O
fap B-Disease
, O
and O
possibly O
with O
importance O
for O
colorectal B-Disease
cancer I-Disease
risk O
in O
the O
general O
population O
. O

. O

genomic O
structure O
of O
the O
human O
congenital B-Disease
chloride I-Disease
diarrhea I-Disease
( O
cld B-Disease
) O
gene O
. O

congenital B-Disease
chloride I-Disease
diarrhea I-Disease
( O
cld B-Disease
) O
is O
caused O
by O
mutations O
in O
a O
gene O
which O
encodes O
an O
intestinal O
anion O
transporter O
. O

we O
report O
here O
the O
complete O
genomic O
organization O
of O
the O
human O
cld B-Disease
gene O
which O
spans O
approximately O
39kb O
, O
and O
comprises O
21 O
exons O
. O

the O
genomic O
structure O
was O
determined O
using O
dna O
from O
several O
sources O
including O
multiple O
large O
- O
insert O
libaries O
and O
genomic O
dna O
from O
finnish O
cld B-Disease
patients O
and O
controls O
. O

genomic O
sequencing O
of O
a O
bac O
clone O
h O
_ O
rg364p16 O
revealed O
the O
presence O
of O
another O
, O
highly O
homologous O
gene O
3 O
of O
the O
cld B-Disease
gene O
, O
with O
a O
similar O
genomic O
structure O
, O
recently O
identified O
as O
the O
pendred B-Disease
syndrome I-Disease
gene O
( O
pds B-Disease
) O
. O

. O

the O
apci1307k O
allele O
and O
cancer B-Disease
risk O
in O
a O
community O
- O
based O
study O
of O
ashkenazi O
jews O
. O

mutations O
in O
apc O
are O
classically O
associated O
with O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
, O
a O
highly O
penetrant O
autosomal B-Disease
dominant I-Disease
disorder I-Disease
characterized O
by O
multiple O
intestinal O
polyps B-Disease
and O
, O
without O
surgical O
intervention O
, O
the O
development O
of O
colorectal B-Disease
cancer I-Disease
( O
crc B-Disease
) O
. O

apc B-Disease
is O
a O
tumour O
- O
suppressor O
gene O
, O
and O
somatic O
loss O
occurs O
in O
tumours B-Disease
. O

1 O
% O
of O
unselected O
ashkenazi O
jews O
and O
higher O
proportions O
of O
ashkenazim O
with O
family O
or O
personal O
histories O
of O
crc B-Disease
( O
ref O
. O

2 O
) O
. O

to O
evaluate O
the O
role O
of O
i1307k O
in O
cancer B-Disease
, O
we O
genotyped O
5 O
, O
81 O
ashkenazi O
volunteers O
in O
a O
community O
survey O
. O

risk O
of O
developing O
colorectal B-Disease
, I-Disease
breast I-Disease
and I-Disease
other I-Disease
cancers I-Disease
were O
compared O
between O
genotyped O
i1307k O
carriers O
and O
non O
- O
carriers O
and O
their O
first O
- O
degree O
relatives O
. O

sperm O
dna O
analysis O
in O
a O
friedreich B-Disease
ataxia I-Disease
premutation O
carrier O
suggests O
both O
meiotic O
and O
mitotic O
expansion O
in O
the O
frda B-Disease
gene O
. O

friedreich B-Disease
ataxia I-Disease
is O
usually O
caused O
by O
an O
expansion O
of O
a O
gaa O
trinucleotide O
repeat O
in O
intron O
1 O
of O
the O
frda B-Disease
gene O
. O

the O
r496h O
mutation O
of O
arylsulfatase O
a O
does O
not O
cause O
metachromatic B-Disease
leukodystrophy I-Disease
. O

deficiency B-Disease
of I-Disease
arylsulfatase I-Disease
a I-Disease
( O
arsa O
) O
enzyme O
activity O
causes O
metachromatic B-Disease
leukodystrophy I-Disease
( O
mld B-Disease
) O
. O

a O
number O
of O
arsa O
gene O
mutations O
responsible O
for O
mld B-Disease
have O
been O
identified O
. O

recently O
, O
the O
r496h O
mutation O
of O
arsa O
was O
proposed O
to O
be O
a O
cause O
of O
mld B-Disease
( O
draghia O
et O
al O
. O

, O
1997 O
) O
. O

it O
is O
therefore O
concluded O
that O
the O
r496h O
mutation O
of O
arsa O
does O
not O
negatively O
influence O
the O
activity O
of O
arsa O
and O
is O
not O
a O
cause O
of O
mld B-Disease
down O
- O
regulation O
of O
transmembrane O
carbonic O
anhydrases O
in O
renal B-Disease
cell I-Disease
carcinoma I-Disease
cell O
lines O
by O
wild O
- O
type O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
transgenes O
. O

to O
discover O
genes O
involved O
in O
von B-Disease
hippel I-Disease
- I-Disease
lindau I-Disease
( O
vhl B-Disease
) O
- O
mediated O
carcinogenesis O
, O
we O
used O
renal B-Disease
cell I-Disease
carcinoma I-Disease
cell O
lines O
stably O
transfected O
with O
wild O
- O
type O
vhl O
- O
expressing O
transgenes O
. O

reintroduced O
wild O
- O
type O
vhl B-Disease
strongly O
inhibited O
the O
overexpression O
of O
the O
ca12 O
gene O
in O
the O
parental O
renal B-Disease
cell I-Disease
carcinoma I-Disease
cell O
lines O
. O

although O
both O
domains O
of O
the O
vhl B-Disease
protein O
contribute O
to O
regulation O
of O
ca12 O
expression O
, O
the O
elongin O
binding O
domain O
alone O
could O
effectively O
regulate O
ca9 O
expression O
. O

2 O
respectively O
, O
regions O
prone O
to O
amplification O
in O
some O
human O
cancers B-Disease
. O

additional O
experiments O
are O
needed O
to O
define O
the O
role O
of O
ca O
ix O
and O
ca O
xii O
enzymes O
in O
the O
regulation O
of O
ph O
in O
the O
extracellular O
microenvironment O
and O
its O
potential O
impact O
on O
cancer B-Disease
cell O
growth O
. O

a O
gene O
encoding O
a O
transmembrane O
protein O
is O
mutated O
in O
patients O
with O
diabetes B-Disease
mellitus I-Disease
and O
optic B-Disease
atrophy I-Disease
( O
wolfram B-Disease
syndrome I-Disease
) O
. O

wolfram B-Disease
syndrome I-Disease
( O
wfs B-Disease
; O
omim O
222300 O
) O
is O
an O
autosomal B-Disease
recessive I-Disease
neurodegenerative I-Disease
disorder I-Disease
defined O
by O
young O
- O
onset O
non O
- O
immune O
insulin B-Disease
- I-Disease
dependent I-Disease
diabetes I-Disease
mellitus I-Disease
and O
progressive O
optic B-Disease
atrophy I-Disease
. O

on O
the O
basis O
of O
meiotic O
recombinants O
and O
disease O
- O
associated O
haplotypes O
, O
the O
wfs B-Disease
gene O
was O
localized O
to O
a O
bac O
/ O
p1 O
contig O
of O
less O
than O
250 O
kb O
. O

mutations O
in O
a O
novel O
gene O
( O
wfs1 O
) O
encoding O
a O
putative O
transmembrane O
protein O
were O
found O
in O
all O
affected O
individuals O
in O
six O
wfs B-Disease
families O
, O
and O
these O
mutations O
were O
associated O
with O
the O
disease O
phenotype O
. O

stable O
interaction O
between O
the O
products O
of O
the O
brca1 O
and O
brca2 O
tumor B-Disease
suppressor O
genes O
in O
mitotic O
and O
meiotic O
cells O
. O

brca1 O
and O
brca2 O
account O
for O
most O
cases O
of O
familial O
, O
early O
onset O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
and O
encode O
products O
that O
each O
interact O
with O
hrad51 O
. O

dysfunction O
of O
this O
pathway O
may O
be O
a O
general O
phenomenon O
in O
the O
majority O
of O
cases O
of O
hereditary B-Disease
breast I-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
. O

. O

a O
novel O
c O
to O
a O
mutation O
in O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
cyp27 O
) O
was O
identified O
by O
sequencing O
amplified O
cyp27 O
gene O
products O
from O
a O
patient O
with O
cerebrotendinous B-Disease
xanthomatosis I-Disease
( O
ctx B-Disease
) O
. O

our O
data O
suggest O
that O
the O
c O
to O
a O
mutation O
at O
the O
penultimate O
nucleotide O
of O
exon O
6 O
of O
the O
cyp27 O
gene O
not O
only O
causes O
the O
deficiency B-Disease
in I-Disease
the I-Disease
sterol I-Disease
27 I-Disease
- I-Disease
hydroxylase I-Disease
activity I-Disease
, O
but O
also O
partially O
leads O
to O
alternative O
pre O
- O
mrna O
splicing O
of O
the O
gene O
. O

atm O
germline O
mutations O
in O
classical O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
patients O
in O
the O
dutch O
population O
. O

germline O
mutations O
in O
the O
atm O
gene O
are O
responsible O
for O
the O
autosomal B-Disease
recessive I-Disease
disorder I-Disease
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
. O

in O
our O
study O
, O
we O
have O
determined O
the O
atm O
mutation O
spectrum O
in O
19 O
classical O
a B-Disease
- I-Disease
t I-Disease
patients O
, O
including O
some O
immigrant O
populations O
, O
as O
well O
as O
12 O
of O
dutch O
ethnic O
origin O
. O

the O
most O
frequently O
found O
mutation O
, O
identified O
in O
three O
unrelated O
turkish O
a B-Disease
- I-Disease
t I-Disease
individuals O
, O
was O
previously O
described O
to O
be O
a O
turkish O
a B-Disease
- I-Disease
t I-Disease
founder O
mutation O
. O

all O
patients O
manifested O
classical O
a B-Disease
- I-Disease
t I-Disease
and O
increased O
cellular O
radioresistant O
dna O
synthesis O
. O

determination O
of O
the O
genomic O
structure O
of O
the O
col4a4 O
gene O
and O
of O
novel O
mutations O
causing O
autosomal B-Disease
recessive I-Disease
alport I-Disease
syndrome I-Disease
. O

autosomal B-Disease
recessive I-Disease
alport I-Disease
syndrome I-Disease
is O
a O
progressive O
hematuric B-Disease
glomerulonephritis I-Disease
characterized O
by O
glomerular B-Disease
basement I-Disease
membrane I-Disease
abnormalities I-Disease
and O
associated O
with O
mutations O
in O
either O
the O
col4a3 O
or O
the O
col4a4 O
gene O
, O
which O
encode O
the O
alpha3 O
and O
alpha4 O
type O
iv O
collagen O
chains O
, O
respectively O
. O

we O
report O
here O
the O
complete O
characterization O
of O
the O
48 O
exons O
of O
the O
col4a4 O
gene O
, O
a O
comprehensive O
gene O
screen O
, O
and O
the O
subsequent O
detection O
of O
10 O
novel O
mutations O
in O
eight O
patients O
diagnosed O
with O
autosomal B-Disease
recessive I-Disease
alport I-Disease
syndrome I-Disease
. O

founder O
brca1 O
and O
brca2 O
mutations O
in O
french O
canadian O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
families O
. O

we O
have O
identified O
four O
mutations O
in O
each O
of O
the O
breast B-Disease
cancer I-Disease
- O
susceptibility O
genes O
, O
brca1 O
and O
brca2 O
, O
in O
french O
canadian O
breast B-Disease
cancer I-Disease
and O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
families O
from O
quebec O
. O

to O
identify O
founder O
effects O
, O
we O
examined O
independently O
ascertained O
french O
canadian O
cancer B-Disease
families O
for O
the O
distribution O
of O
these O
eight O
mutations O
. O

7x O
greater O
if O
one O
or O
more O
cases O
of O
ovarian B-Disease
cancer I-Disease
were O
also O
present O
in O
the O
family O
. O

3x O
greater O
if O
there O
were O
at O
least O
five O
cases O
of O
breast B-Disease
cancer I-Disease
in O
the O
family O
. O

interestingly O
, O
the O
presence O
of O
a O
breast B-Disease
cancer I-Disease
case O
< O
36 O
years O
of O
age O
was O
strongly O
predictive O
of O
the O
presence O
of O
any O
of O
the O
eight O
mutations O
screened O
. O

the O
identification O
of O
common O
brca1 O
and O
brca2 O
mutations O
will O
facilitate O
carrier O
detection O
in O
french O
canadian O
breast B-Disease
cancer I-Disease
and O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
families O
. O

are O
dp71 O
and O
dp140 O
brain O
dystrophin O
isoforms O
related O
to O
cognitive B-Disease
impairment I-Disease
in O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
? O
molecular O
study O
and O
neuropsychological O
analysis O
were O
performed O
concurrently O
on O
49 O
patients O
with O
duchenne B-Disease
muscular I-Disease
dystrophy I-Disease
( O
dmd B-Disease
) O
in O
order O
to O
find O
a O
molecular O
explanation O
for O
the O
cognitive B-Disease
impairment I-Disease
observed O
in O
most O
dmd B-Disease
patients O
. O

complete O
analysis O
of O
the O
dystrophin O
gene O
was O
performed O
to O
define O
the O
localization O
of O
deletions O
and O
duplications O
in O
relation O
to O
the O
different O
dmd B-Disease
promoters O
. O

comparison O
of O
molecular O
and O
psychometric O
findings O
demonstrated O
that O
deletions O
and O
duplications O
that O
were O
localized O
in O
the O
distal O
part O
of O
the O
gene O
seemed O
to O
be O
preferentially O
associated O
with O
cognitive B-Disease
impairment I-Disease
. O

two O
altered O
dp71 O
transcripts O
and O
two O
deleted O
dp140 O
dna O
sequences O
were O
found O
in O
four O
patients O
with O
severe O
cerebral B-Disease
dysfunction I-Disease
. O

these O
findings O
suggest O
that O
some O
sequences O
located O
in O
the O
distal O
part O
of O
the O
gene O
and O
, O
in O
particular O
, O
some O
dmd B-Disease
isoforms O
expressed O
in O
the O
brain O
may O
be O
related O
to O
the O
cognitive B-Disease
impairment I-Disease
associated O
with O
dmd B-Disease
. O

. O

i1307k O
apc O
and O
hmlh1 O
mutations O
in O
a O
non O
- O
jewish O
family O
with O
hereditary B-Disease
non I-Disease
- I-Disease
polyposis I-Disease
colorectal I-Disease
cancer I-Disease
. O

we O
describe O
a O
french O
canadian O
hereditary B-Disease
non I-Disease
- I-Disease
polyposis I-Disease
colorectal I-Disease
cancer I-Disease
( O
hnpcc B-Disease
) O
kindred O
which O
carries O
a O
novel O
truncating O
mutation O
in O
hmlh1 O
. O

interestingly O
, O
the O
i1307k O
apc O
polymorphism O
, O
associated O
with O
an O
increased O
risk O
of O
colorectal B-Disease
cancer I-Disease
, O
is O
also O
present O
in O
this O
family O
. O

in O
addition O
, O
in O
this O
family O
, O
there O
appears O
to O
be O
no O
relationship O
between O
the O
i1307k O
polymorphism O
and O
the O
presence O
or O
absence O
of O
cancer B-Disease
. O

identification O
of O
a O
novel O
mutation O
of O
the O
cpo O
gene O
in O
a O
japanese O
hereditary B-Disease
coproporphyria I-Disease
family O
. O

hereditary B-Disease
coproporphyria I-Disease
( O
hcp B-Disease
) O
is O
an O
autosomal B-Disease
dominant I-Disease
disease I-Disease
characterized O
by O
a O
deficiency B-Disease
of I-Disease
coproporphyrinogen I-Disease
oxidase I-Disease
( O
cpo O
) O
caused O
by O
a O
mutation O
in O
the O
cpo O
gene O
. O

only O
11 O
mutations O
of O
the O
gene O
have O
been O
reported O
in O
hcp B-Disease
patients O
. O

human B-Disease
complement I-Disease
factor I-Disease
h I-Disease
deficiency I-Disease
associated O
with O
hemolytic B-Disease
uremic I-Disease
syndrome I-Disease
. O

this O
study O
reports O
on O
six O
cases O
of O
deficiency B-Disease
in I-Disease
the I-Disease
human I-Disease
complement I-Disease
regulatory I-Disease
protein I-Disease
factor I-Disease
h I-Disease
( O
fh O
) O
in O
the O
context O
of O
an O
acute B-Disease
renal I-Disease
disease I-Disease
. O

five O
of O
the O
cases O
were O
observed O
in O
children O
presenting O
with O
idiopathic O
hemolytic B-Disease
uremic I-Disease
syndrome I-Disease
( O
hus B-Disease
) O
. O

factor B-Disease
h I-Disease
deficiency I-Disease
is O
the O
only O
complement B-Disease
deficiency I-Disease
associated O
with O
hus B-Disease
. O

these O
observations O
suggest O
a O
role O
for O
fh O
and O
/ O
or O
fh O
receptors O
in O
the O
pathogenesis O
of O
idiopathic O
hus B-Disease
. O

. O

further O
evidence O
for O
a O
major O
ancient O
mutation O
underlying O
myotonic B-Disease
dystrophy I-Disease
from O
linkage O
disequilibrium O
studies O
in O
the O
japanese O
population O
. O

the O
myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
mutation O
is O
an O
unstable O
( O
ctg O
) O
n O
repeat O
, O
present O
at O
a O
copy O
number O
of O
5 O
- O
37 O
repeats O
on O
normal O
chromosomes O
but O
amplified O
to O
50 O
- O
3000 O
copies O
on O
dm B-Disease
chromosomes O
. O

previous O
findings O
in O
caucasian O
populations O
of O
a O
dm B-Disease
founder O
chromosome O
raise O
a O
question O
about O
the O
molecular O
events O
involved O
in O
the O
expansion O
mutation O
. O

to O
investigate O
whether O
a O
founder O
chromosome O
for O
the O
dm B-Disease
mutation O
exists O
in O
the O
japanese O
population O
, O
we O
genotyped O
families O
using O
polymorphic O
markers O
near O
the O
( O
ctg O
) O
n O
repeat O
region O
and O
constructed O
haplotypes O
. O

six O
different O
haplotypes O
were O
found O
and O
dm B-Disease
alleles O
were O
always O
haplotype O
a O
. O

to O
find O
an O
origin O
of O
the O
( O
ctg O
) O
n O
repeat O
mutation O
and O
to O
investigate O
the O
mechanism O
of O
the O
expansion O
mutation O
in O
the O
japanese O
population O
we O
have O
studied O
90 O
japanese O
dm B-Disease
families O
comprising O
190 O
affected O
and O
130 O
unaffected O
members O
. O

these O
data O
support O
multistep O
models O
of O
triplet O
repeat O
expansion O
that O
have O
been O
proposed O
for O
both O
dm B-Disease
and O
friedreichs B-Disease
ataxia I-Disease
. O

. O

the O
molecular O
basis O
of O
c6 B-Disease
deficiency I-Disease
in O
the O
western O
cape O
, O
south O
africa O
. O

deficiency B-Disease
of I-Disease
the I-Disease
sixth I-Disease
component I-Disease
of I-Disease
human I-Disease
complement I-Disease
( O
c6 O
) O
has O
been O
reported O
in O
a O
number O
of O
families O
from O
the O
western O
cape O
, O
south O
africa O
. O

meningococcal B-Disease
disease I-Disease
is O
endemic O
in O
the O
cape O
and O
almost O
all O
pedigrees O
of O
total O
c6 B-Disease
deficiency I-Disease
( O
c6q0 O
) O
have O
been O
ascertained O
because O
of O
recurrent O
disease O
. O

we O
have O
also O
observed O
the O
879delg O
defect O
in O
two O
dutch O
c6 B-Disease
- I-Disease
deficient I-Disease
kindreds O
, O
but O
the O
879delg O
defect O
in O
the O
cape O
probably O
did O
not O
come O
from O
the O
netherlands O
. O

. O

complement B-Disease
c7 I-Disease
deficiency I-Disease
: O
seven O
further O
molecular O
defects O
and O
their O
associated O
marker O
haplotypes O
. O

seven O
further O
molecular O
bases O
of O
c7 B-Disease
deficiency I-Disease
are O
described O
. O

the O
c6 O
/ O
c7 O
marker O
haplotypes O
associated O
with O
most O
c7 B-Disease
defects I-Disease
are O
tabulated O
. O

. O

a O
genome O
- O
wide O
search O
for O
chromosomal O
loci O
linked O
to O
mental O
health O
wellness O
in O
relatives O
at O
high O
risk O
for O
bipolar B-Disease
affective I-Disease
disorder I-Disease
among O
the O
old O
order O
amish O
. O

bipolar B-Disease
affective I-Disease
disorder I-Disease
( O
bpad B-Disease
; O
manic B-Disease
- I-Disease
depressive I-Disease
illness I-Disease
) O
is O
characterized O
by O
episodes O
of O
mania B-Disease
and O
/ O
or O
hypomania B-Disease
interspersed O
with O
periods O
of O
depression B-Disease
. O

compelling O
evidence O
supports O
a O
significant O
genetic O
component O
in O
the O
susceptibility O
to O
develop O
bpad B-Disease
. O

to O
date O
, O
however O
, O
linkage O
studies O
have O
attempted O
only O
to O
identify O
chromosomal O
loci O
that O
cause O
or O
increase O
the O
risk O
of O
developing O
bpad B-Disease
. O

to O
determine O
whether O
there O
could O
be O
protective O
alleles O
that O
prevent O
or O
reduce O
the O
risk O
of O
developing O
bpad B-Disease
, O
similar O
to O
what O
is O
observed O
in O
other O
genetic B-Disease
disorders I-Disease
, O
we O
used O
mental O
health O
wellness O
( O
absence O
of O
any O
psychiatric B-Disease
disorder I-Disease
) O
as O
the O
phenotype O
in O
our O
genome O
- O
wide O
linkage O
scan O
of O
several O
large O
multigeneration O
old O
order O
amish O
pedigrees O
exhibiting O
an O
extremely O
high O
incidence O
of O
bpad B-Disease
. O

these O
findings O
are O
consistent O
with O
the O
hypothesis O
that O
certain O
alleles O
could O
prevent O
or O
modify O
the O
clinical O
manifestations O
of O
bpad B-Disease
and O
perhaps O
other O
related O
affective B-Disease
disorders I-Disease
. O

segregation O
distortion O
in O
myotonic B-Disease
dystrophy I-Disease
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
an O
autosomal B-Disease
dominant I-Disease
disease I-Disease
which O
, O
in O
the O
typical O
pedigree O
, O
shows O
a O
three O
generation O
anticipation O
cascade O
. O

this O
results O
in O
infertility B-Disease
and O
congenital B-Disease
myotonic I-Disease
dystrophy I-Disease
( O
cdm B-Disease
) O
with O
the O
disappearance O
of O
dm B-Disease
in O
that O
pedigree O
. O

the O
concept O
of O
segregation O
distortion O
, O
where O
there O
is O
preferential O
transmission O
of O
the O
larger O
allele O
at O
the O
dm B-Disease
locus O
, O
has O
been O
put O
forward O
to O
explain O
partially O
the O
maintenance O
of O
dm B-Disease
in O
the O
population O
. O

in O
a O
survey O
of O
dm B-Disease
in O
northern O
ireland O
, O
59 O
pedigrees O
were O
ascertained O
. O

sibships O
where O
the O
status O
of O
all O
the O
members O
had O
been O
identified O
were O
examined O
to O
determine O
the O
transmission O
of O
the O
dm B-Disease
expansion O
from O
affected O
parents O
to O
their O
offspring O
. O

studies O
on O
meiotic O
drive O
in O
dm B-Disease
have O
shown O
increased O
transmission O
of O
the O
larger O
allele O
at O
the O
dm B-Disease
locus O
in O
non O
- O
dm O
heterozygotes O
for O
ctgn O
. O

this O
study O
provides O
further O
evidence O
that O
the O
dm B-Disease
expansion O
tends O
to O
be O
transmitted O
preferentially O
. O

diagnosis O
of O
hemochromatosis B-Disease
. O

if O
untreated O
, O
hemochromatosis B-Disease
can O
cause O
serious O
illness O
and O
early B-Disease
death I-Disease
, O
but O
the O
disease O
is O
still O
substantially O
under O
- O
diagnosed O
. O

once O
the O
diagnosis O
is O
suspected O
, O
physicians O
must O
use O
serum O
ferritin O
levels O
and O
hepatic O
iron O
stores O
on O
liver O
biopsy O
specimens O
to O
assess O
patients O
for O
the O
presence O
of O
iron B-Disease
overload I-Disease
. O

liver O
biopsy O
is O
also O
used O
to O
establish O
the O
presence O
or O
absence O
of O
cirrhosis B-Disease
, O
which O
can O
affect O
prognosis O
and O
management O
. O

a O
dna O
- O
based O
test O
for O
the O
hfe O
gene O
is O
commercially O
available O
, O
but O
its O
place O
in O
the O
diagnosis O
of O
hemochromatosis B-Disease
is O
still O
being O
evaluated O
. O

currently O
, O
the O
most O
useful O
role O
for O
this O
test O
is O
in O
the O
detection O
of O
hemochromatosis B-Disease
in O
the O
family O
members O
of O
patients O
with O
a O
proven O
case O
of O
the O
disease O
. O

it O
is O
crucial O
to O
diagnose O
hemochromatosis B-Disease
before O
hepatic B-Disease
cirrhosis I-Disease
develops O
because O
phlebotomy O
therapy O
can O
avert O
serious O
chronic O
disease O
and O
can O
even O
lead O
to O
normal O
life O
expectancy O
. O

. O

prevalence O
of O
the O
i1307k O
apc B-Disease
gene O
variant O
in O
israeli O
jews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
colorectal B-Disease
cancer I-Disease
. O

background O
& O
aims O
israeli O
jews O
of O
european O
birth O
, O
i O
. O

e O
. O

, O
ashkenazim O
, O
have O
the O
highest O
colorectal B-Disease
cancer I-Disease
incidence O
of O
any O
israeli O
ethnic O
group O
. O

the O
i1307k O
apc B-Disease
gene O
variant O
was O
found O
in O
6 O
. O

1 O
% O
of O
american O
jews O
, O
28 O
% O
of O
their O
familial O
colorectal B-Disease
cancer I-Disease
cases O
, O
but O
not O
in O
non O
- O
jews O
. O

we O
assessed O
the O
i1307k O
prevalence O
in O
israeli O
jews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
colorectal B-Disease
cancer I-Disease
. O

methods O
dna O
samples O
from O
500 O
unrelated O
jews O
of O
european O
or O
non O
- O
european O
origin O
, O
with O
or O
without O
a O
personal O
and O
/ O
or O
family O
history O
of O
neoplasia B-Disease
, O
were O
examined O
for O
the O
i1307k O
variant O
by O
the O
allele O
- O
specific O
oligonucleotide O
( O
aso O
) O
method O
. O

results O
in O
persons O
at O
average O
risk O
for O
colorectal B-Disease
cancer I-Disease
, O
i1307k O
was O
found O
in O
5 O
. O

4 O
% O
of O
52 O
ashkenazi O
israelis O
with O
familial O
cancer B-Disease
( O
p O
= O
0 O
. O

2 O
) O
and O
was O
not O
detected O
in O
51 O
non O
- O
european O
jews O
at O
increased O
cancer B-Disease
risk O
. O

colorectal B-Disease
neoplasia I-Disease
occurred O
personally O
or O
in O
the O
families O
of O
13 O
of O
20 O
ashkenazi O
i1307k O
carriers O
, O
8 O
of O
whom O
also O
had O
a O
personal O
or O
family O
history O
of O
noncolonic O
neoplasia B-Disease
. O

conclusions O
the O
i1307k O
apc O
variant O
may O
represent O
a O
susceptibility O
gene O
for O
colorectal B-Disease
, I-Disease
or I-Disease
other I-Disease
, I-Disease
cancers I-Disease
in O
ashkenazi O
jews O
, O
and O
partially O
explains O
the O
higher O
incidence O
of O
colorectal B-Disease
cancer I-Disease
in O
european O
israelis O
. O

systematic O
analysis O
of O
coproporphyrinogen O
oxidase O
gene O
defects O
in O
hereditary B-Disease
coproporphyria I-Disease
and O
mutation O
update O
. O

hereditary B-Disease
coproporphyria I-Disease
( O
hc B-Disease
) O
is O
an O
acute O
hepatic B-Disease
porphyria I-Disease
with O
autosomal O
dominant O
inheritance O
caused O
by O
deficient B-Disease
activity I-Disease
of I-Disease
coproporphyrinogen I-Disease
iii I-Disease
oxidase I-Disease
( O
cpo O
) O
. O

clinical O
manifestations O
of O
the O
disease O
are O
characterized O
by O
acute O
attacks O
of O
neurological B-Disease
dysfunction I-Disease
often O
precipitated O
by O
drugs O
, O
fasting O
, O
cyclical O
hormonal O
changes O
, O
or O
infectious B-Disease
diseases I-Disease
. O

the O
seven O
exons O
, O
the O
exon O
/ O
intron O
boundaries O
and O
part O
of O
3 O
noncoding O
sequence O
of O
the O
cpo O
gene O
were O
systematically O
analyzed O
by O
an O
exon O
- O
by O
- O
exon O
denaturing O
gradient O
gel O
electrophoresis O
( O
dgge O
) O
strategy O
followed O
by O
direct O
sequencing O
in O
seven O
unrelated O
heterozygous O
hc B-Disease
patients O
from O
france O
, O
holland O
, O
and O
czech O
republic O
. O

five O
intragenic O
dimorphisms O
are O
now O
well O
characterized O
and O
the O
high O
degree O
of O
allelic O
heterogeneity O
in O
hc B-Disease
is O
demonstrated O
with O
seven O
new O
different O
mutations O
making O
a O
total O
of O
nineteen O
cpo O
gene B-Disease
defects I-Disease
reported O
so O
far O
. O

. O

coincidence O
of O
two O
novel O
arylsulfatase O
a O
alleles O
and O
mutation O
459 O
+ O
1g O
> O
a O
within O
a O
family O
with O
metachromatic B-Disease
leukodystrophy I-Disease
: O
molecular O
basis O
of O
phenotypic O
heterogeneity O
. O

in O
a O
family O
with O
three O
siblings O
, O
one O
developed O
classical O
late O
infantile O
metachromatic B-Disease
leukodystrophy I-Disease
( O
mld B-Disease
) O
, O
fatal O
at O
age O
5 O
years O
, O
with O
deficient O
arylsulfatase O
a O
( O
arsa O
) O
activity O
and O
increased O
galactosylsulfatide O
( O
gs O
) O
excretion O
. O

the O
two O
other O
siblings O
, O
apparently O
healthy O
at O
12 O
( O
1 O
/ O
2 O
) O
and O
15 O
years O
, O
respectively O
, O
and O
their O
father O
, O
apparently O
healthy O
as O
well O
, O
presented O
arsa O
and O
gs O
values O
within O
the O
range O
of O
mld B-Disease
patients O
. O

mutation O
a464v O
was O
not O
found O
in O
18 O
unrelated O
mld B-Disease
patients O
and O
50 O
controls O
. O

a464v O
, O
although O
clearly O
modifying O
arsa O
and O
gs O
levels O
, O
apparently O
bears O
little O
significance O
for O
clinical O
manifestation O
of O
mld B-Disease
, O
mimicking O
the O
frequent O
arsa O
pseudodeficiency O
allele O
. O

our O
results O
demonstrate O
that O
in O
certain O
genetic O
conditions O
mld B-Disease
- O
like O
arsa O
and O
gs O
values O
need O
not O
be O
paralleled O
by O
clinical O
disease O
, O
a O
finding O
with O
serious O
diagnostic O
and O
prognostic O
implications O
. O

human O
mlh1 O
deficiency O
predisposes O
to O
hematological B-Disease
malignancy I-Disease
and O
neurofibromatosis B-Disease
type I-Disease
1 I-Disease
. O

heterozygous O
germ O
- O
line O
mutations O
in O
the O
dna O
mismatch O
repair O
genes O
lead O
to O
hereditary B-Disease
nonpolyposis I-Disease
colorectal I-Disease
cancer I-Disease
. O

we O
have O
identified O
three O
offspring O
in O
a O
hereditary B-Disease
nonpolyposis I-Disease
colorectal I-Disease
cancer I-Disease
family O
who O
developed O
hematological B-Disease
malignancy I-Disease
at O
a O
very O
early O
age O
, O
and O
at O
least O
two O
of O
them O
displayed O
signs O
of O
neurofibromatosis B-Disease
type I-Disease
1 I-Disease
( O
nf1 B-Disease
) O
. O

thus O
, O
a O
homozygous O
germ O
- O
line O
mlh1 O
mutation O
and O
consequent O
mismatch O
repair O
deficiency O
results O
in O
a O
mutator O
phenotype O
characterized O
by O
leukemia B-Disease
and O
/ O
or O
lymphoma B-Disease
associated O
with O
neurofibromatosis B-Disease
type I-Disease
1 I-Disease
. O

. O

missense O
mutations O
in O
the O
most O
ancient O
residues O
of O
the O
pax6 O
paired O
domain O
underlie O
a O
spectrum O
of O
human O
congenital B-Disease
eye I-Disease
malformations I-Disease
. O

mutations O
of O
the O
human O
pax6 O
gene O
underlie O
aniridia B-Disease
( O
congenital B-Disease
absence I-Disease
of I-Disease
the I-Disease
iris I-Disease
) O
, O
a O
rare O
dominant O
malformation B-Disease
of I-Disease
the I-Disease
eye I-Disease
. O

the O
spectrum O
of O
pax6 O
mutations O
in O
aniridia B-Disease
patients O
is O
highly O
biased O
, O
with O
92 O
% O
of O
all O
reported O
mutations O
leading O
to O
premature O
truncation O
of O
the O
protein O
( O
nonsense O
, O
splicing O
, O
insertions O
and O
deletions O
) O
and O
just O
2 O
% O
leading O
to O
substitution O
of O
one O
amino O
acid O
by O
another O
( O
missense O
) O
. O

the O
extraordinary O
conservation O
of O
the O
pax6 O
protein O
at O
the O
amino O
acid O
level O
amongst O
vertebrates O
predicts O
that O
pathological O
missense O
mutations O
should O
in O
fact O
be O
common O
even O
though O
they O
are O
hardly O
ever O
seen O
in O
aniridia B-Disease
patients O
. O

this O
indicates O
that O
there O
is O
a O
heavy O
ascertainment O
bias O
in O
the O
selection O
of O
patients O
for O
pax6 O
mutation O
analysis O
and O
that O
the O
missing O
pax6 O
missense O
mutations O
frequently O
may O
underlie O
phenotypes O
distinct O
from O
textbook O
aniridia B-Disease
. O

here O
we O
present O
four O
novel O
pax6 O
missense O
mutations O
, O
two O
in O
association O
with O
atypical O
phenotypes O
ectopia B-Disease
pupillae I-Disease
( O
displaced B-Disease
pupils I-Disease
) O
and O
congenital B-Disease
nystagmus I-Disease
( O
searching B-Disease
gaze I-Disease
) O
, O
and O
two O
in O
association O
with O
more O
recognizable O
aniridia B-Disease
phenotypes O
. O

our O
results O
support O
the O
hypothesis O
that O
the O
under O
- O
representation O
of O
missense O
mutations O
is O
caused O
by O
ascertainment O
bias O
and O
suggest O
that O
a O
substantial O
burden O
of O
pax6 B-Disease
- I-Disease
related I-Disease
disease I-Disease
remains O
to O
be O
uncovered O
. O

. O

the O
chromosomal O
order O
of O
genes O
controlling O
the O
major O
histocompatibility O
complex O
, O
properdin O
factor O
b O
, O
and O
deficiency B-Disease
of I-Disease
the I-Disease
second I-Disease
component I-Disease
of I-Disease
complement I-Disease
. O

the O
relationship O
of O
the O
genes O
coding O
for O
hla O
to O
those O
coding O
for O
properdin O
factor O
b O
allotypes O
and O
for O
deficiency B-Disease
of I-Disease
the I-Disease
second I-Disease
component I-Disease
of I-Disease
complement I-Disease
( O
c2 O
) O
was O
studied O
in O
families O
of O
patients O
with O
connective O
tissue O
disorders O
. O

patients O
were O
selected O
because O
they O
were O
heterozygous O
or O
homozygous O
for O
c2 B-Disease
deficiency I-Disease
. O

12 O
families O
with O
15 O
matings O
informative O
for O
c2 B-Disease
deficiency I-Disease
were O
found O
. O

of O
57 O
informative O
meioses O
, O
two O
crossovers O
were O
noted O
between O
the O
c2 B-Disease
deficiency I-Disease
gene O
and O
the O
hla O
- O
b O
gene O
, O
with O
a O
recombinant O
fraction O
of O
0 O
. O

a O
lod O
score O
of O
13 O
was O
calculated O
for O
linkage O
between O
c2 B-Disease
deficiency I-Disease
and O
hla O
- O
b O
at O
a O
maximum O
likelihood O
value O
of O
the O
recombinant O
fraction O
of O
0 O
. O

these O
studies O
suggest O
that O
the O
genes O
for O
factor O
b O
and O
c2 B-Disease
deficiency I-Disease
are O
located O
outside O
those O
for O
hla O
, O
that O
the O
order O
of O
genese O
is O
hla O
- O
a O
, O
- O
b O
, O
- O
d O
, O
factor O
b O
allotype O
, O
c2 B-Disease
deficiency I-Disease
, O
that O
the O
genes O
coding O
for O
c2 B-Disease
deficiency I-Disease
and O
factor O
b O
allotypes O
are O
approximately O
3 O
- O
- O
5 O
centimorgans O
from O
the O
hla O
- O
a O
and O
hla O
- O
b O
loci O
, O
and O
that O
the O
apparent O
lack O
of O
recombinants O
between O
the O
factor O
b O
gene O
and O
c2 B-Disease
deficiency I-Disease
gene O
suggests O
that O
these O
two O
genes O
lie O
in O
close O
proximity O
to O
one O
another O
. O

distribution O
of O
emerin O
and O
lamins O
in O
the O
heart O
and O
implications O
for O
emery B-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
. O

emerin O
is O
a O
nuclear O
membrane O
protein O
which O
is O
missing O
or O
defective O
in O
emery B-Disease
- I-Disease
dreifuss I-Disease
muscular I-Disease
dystrophy I-Disease
( O
edmd B-Disease
) O
. O

these O
results O
would O
not O
be O
expected O
if O
immunostaining O
at O
intercalated O
discs O
were O
due O
to O
a O
product O
of O
the O
emerin O
gene O
and O
, O
therefore O
, O
cast O
some O
doubt O
upon O
the O
hypothesis O
that O
cardiac B-Disease
defects I-Disease
in O
edmd B-Disease
are O
caused O
by O
absence O
of O
emerin O
from O
intercalated O
discs O
. O

this O
distribution O
of O
emerin O
was O
similar O
to O
that O
of O
lamin O
a O
, O
a O
candidate O
gene O
for O
an O
autosomal O
form O
of O
edmd B-Disease
. O

in O
edmd B-Disease
, O
the O
additional O
absence O
of O
lamin O
b1 O
from O
heart O
and O
skeletal O
muscle O
nuclei O
which O
already O
lack O
emerin O
may O
offer O
an O
alternative O
explanation O
of O
why O
these O
tissues O
are O
particularly O
affected O
. O

. O

genetic O
mapping O
of O
the O
copper B-Disease
toxicosis I-Disease
locus O
in O
bedlington O
terriers O
to O
dog O
chromosome O
10 O
, O
in O
a O
region O
syntenic O
to O
human O
chromosome O
region O
2p13 O
- O
p16 O
. O

abnormal O
hepatic B-Disease
copper I-Disease
accumulation I-Disease
is O
recognized O
as O
an O
inherited B-Disease
disorder I-Disease
in O
man O
, O
mouse O
, O
rat O
and O
dog O
. O

the O
major O
cause O
of O
hepatic B-Disease
copper I-Disease
accumulation I-Disease
in O
man O
is O
a O
dysfunctional O
atp7b O
gene O
, O
causing O
wilson B-Disease
disease I-Disease
( O
wd B-Disease
) O
. O

the O
atp7b O
gene O
has O
been O
excluded O
in O
the O
much O
rarer O
human O
copper B-Disease
overload I-Disease
disease O
non B-Disease
- I-Disease
indian I-Disease
childhood I-Disease
cirrhosis I-Disease
, O
indicating O
genetic O
heterogeneity O
. O

by O
investigating O
the O
common O
autosomal O
recessive O
copper B-Disease
toxicosis I-Disease
( O
ct B-Disease
) O
in O
bedlington O
terriers O
, O
we O
have O
identified O
a O
new O
locus O
involved O
in O
progressive O
liver B-Disease
disease I-Disease
. O

we O
examined O
whether O
the O
wd B-Disease
gene O
atp7b O
was O
also O
causative O
for O
ct B-Disease
by O
investigating O
the O
chromosomal O
co O
- O
localization O
of O
atp7b O
and O
c04107 O
, O
using O
fluorescence O
in O
situ O
hybridization O
( O
fish O
) O
. O

c04107 O
is O
an O
anonymous O
microsatellite O
marker O
closely O
linked O
to O
ct B-Disease
. O

however O
, O
bac O
clones O
containing O
atp7b O
and O
c04107 O
mapped O
to O
the O
canine O
chromosome O
regions O
cfa22q11 O
and O
cfa10q26 O
, O
respectively O
, O
demonstrating O
that O
wd B-Disease
cannot O
be O
homologous O
to O
ct B-Disease
. O

the O
copper O
transport O
genes O
ctr1 O
and O
ctr2 O
were O
also O
excluded O
as O
candidate O
genes O
for O
ct B-Disease
since O
they O
both O
mapped O
to O
canine O
chromosome O
region O
cfa11q22 O
. O

molecular O
analysis O
of O
the O
apc B-Disease
gene O
in O
205 O
families O
: O
extended O
genotype O
- O
phenotype O
correlations O
in O
fap B-Disease
and O
evidence O
for O
the O
role O
of O
apc B-Disease
amino O
acid O
changes O
in O
colorectal B-Disease
cancer I-Disease
predisposition O
. O

background O
/ O
aims O
the O
development O
of O
colorectal B-Disease
cancer I-Disease
and O
a O
variable O
range O
of O
extracolonic O
manifestations O
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
( O
fap B-Disease
) O
is O
the O
result O
of O
the O
dominant O
inheritance O
of O
adenomatous B-Disease
polyposis I-Disease
coli I-Disease
( O
apc B-Disease
) O
gene O
mutations O
. O

in O
this O
study O
, O
direct O
mutation O
analysis O
of O
the O
apc B-Disease
gene O
was O
performed O
to O
determine O
genotype O
- O
phenotype O
correlations O
for O
nine O
extracolonic O
manifestations O
and O
to O
investigate O
the O
incidence O
of O
apc B-Disease
mutations O
in O
non O
- O
fap O
colorectal B-Disease
cancer I-Disease
. O

methods O
the O
apc B-Disease
gene O
was O
analysed O
in O
190 O
unrelated O
fap B-Disease
and O
15 O
non O
- O
fap O
colorectal B-Disease
cancer I-Disease
patients O
using O
denaturing O
gradient O
gel O
electrophoresis O
, O
the O
protein O
truncation O
test O
, O
and O
direct O
sequencing O
. O

results O
chain O
terminating O
signals O
were O
only O
identified O
in O
patients O
belonging O
to O
the O
fap B-Disease
group O
( O
105 O
patients O
) O
. O

amino O
acid O
changes O
were O
identified O
in O
four O
patients O
, O
three O
of O
whom O
belonged O
to O
the O
non O
- O
fap O
group O
of O
colorectal B-Disease
cancer I-Disease
patients O
. O

genotype O
- O
phenotype O
correlations O
identified O
significant O
differences O
in O
the O
nature O
of O
certain O
extracolonic O
manifestations O
in O
fap B-Disease
patients O
belonging O
to O
three O
mutation O
subgroups O
. O

this O
study O
also O
provided O
evidence O
for O
the O
pathological O
nature O
of O
amino O
acid O
changes O
in O
apc O
associated O
with O
both O
fap B-Disease
and O
non O
- O
fap O
colorectal B-Disease
cancer I-Disease
patients O
. O

. O

inherited B-Disease
colorectal I-Disease
polyposis I-Disease
and O
cancer B-Disease
risk O
of O
the O
apc O
i1307k O
polymorphism O
. O

germ O
- O
line O
and O
somatic O
truncating O
mutations O
of O
the O
apc B-Disease
gene O
are O
thought O
to O
initiate O
colorectal B-Disease
tumor I-Disease
formation O
in O
familial B-Disease
adenomatous I-Disease
polyposis I-Disease
syndrome I-Disease
and O
sporadic O
colorectal O
carcinogenesis O
, O
respectively O
. O

recently O
, O
an O
isoleucine O
- O
- O
> O
lysine O
polymorphism O
at O
codon O
1307 O
( O
i1307k O
) O
of O
the O
apc B-Disease
gene O
has O
been O
identified O
in O
6 O
% O
- O
7 O
% O
of O
the O
ashkenazi O
jewish O
population O
. O

to O
assess O
the O
risk O
of O
this O
common O
apc B-Disease
allelic O
variant O
in O
colorectal O
carcinogenesis O
, O
we O
have O
analyzed O
a O
large O
cohort O
of O
unselected O
ashkenazi O
jewish O
subjects O
with O
adenomatous B-Disease
polyps I-Disease
and O
. O

or O
colorectal B-Disease
cancer I-Disease
, I-Disease
for O
the O
apc O
i1307k O
polymorphism O
. O

7 O
for O
colorectal B-Disease
neoplasia I-Disease
( O
both O
p O
= O
. O

1 O
) O
. O

furthermore O
, O
compared O
with O
noncarriers O
, O
apc O
i1307k O
carriers O
had O
increased O
numbers O
of O
adenomas B-Disease
and O
colorectal B-Disease
cancers I-Disease
per O
patient O
( O
p O
= O
. O

3 O
) O
, O
as O
well O
as O
a O
younger O
age O
at O
diagnosis O
. O

we O
conclude O
that O
the O
apc O
i1307k O
variant O
leads O
to O
increased O
adenoma B-Disease
formation O
and O
directly O
contributes O
to O
3 O
% O
- O
4 O
% O
of O
all O
ashkenazi O
jewish O
colorectal B-Disease
cancer I-Disease
. O

the O
estimated O
relative O
risk O
for O
carriers O
may O
justify O
specific O
clinical O
screening O
for O
the O
360 O
, O
0 O
americans O
expected O
to O
harbor O
this O
allele O
, O
and O
genetic O
testing O
in O
the O
setting O
of O
long O
- O
term O
- O
outcome O
studies O
may O
impact O
significantly O
on O
colorectal B-Disease
cancer I-Disease
prevention O
in O
this O
population O
. O

localization O
of O
human O
brca1 O
and O
its O
loss O
in O
high O
- O
grade O
, O
non B-Disease
- I-Disease
inherited I-Disease
breast I-Disease
carcinomas I-Disease
. O

although O
the O
link O
between O
the O
brca1 O
tumour B-Disease
- O
suppressor O
gene O
and O
hereditary B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
is O
established O
, O
the O
role O
, O
if O
any O
, O
of O
brca1 O
in O
non B-Disease
- I-Disease
familial I-Disease
cancers I-Disease
is O
unclear O
. O

brca1 O
mutations O
are O
rare O
in O
sporadic B-Disease
cancers I-Disease
, O
but O
loss O
of O
brca1 O
resulting O
from O
reduced O
expression O
or O
incorrect O
subcellular O
localization O
is O
postulated O
to O
be O
important O
in O
non B-Disease
- I-Disease
familial I-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
. O

these O
reagents O
detect O
a O
220 O
- O
kd O
protein O
localized O
in O
discrete O
nuclear O
foci O
in O
all O
epithelial O
cell O
lines O
, O
including O
those O
derived O
from O
breast B-Disease
malignancies I-Disease
. O

immunohistochemical O
staining O
of O
human O
breast O
specimens O
also O
revealed O
brca1 O
nuclear O
foci O
in O
benign O
breast O
, O
invasive B-Disease
lobular I-Disease
cancers I-Disease
and O
low B-Disease
- I-Disease
grade I-Disease
ductal I-Disease
carcinomas I-Disease
. O

conversely O
, O
brca1 O
expression O
was O
reduced O
or O
undetectable O
in O
the O
majority O
of O
high O
- O
grade O
, O
ductal B-Disease
carcinomas I-Disease
, O
suggesting O
that O
absence O
of O
brca1 O
may O
contribute O
to O
the O
pathogenesis O
of O
a O
significant O
percentage O
of O
sporadic B-Disease
breast I-Disease
cancers I-Disease
. O

germline O
mutations O
in O
brca1 O
are O
responsible O
for O
most O
cases O
of O
inherited B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
. O

as O
a O
regulated O
secretory O
protein O
, O
brca1 O
appears O
to O
function O
by O
a O
mechanism O
not O
previously O
described O
for O
tumour B-Disease
suppressor O
gene O
products O
. O

. O

ovarian B-Disease
cancer I-Disease
risk O
in O
brca1 O
carriers O
is O
modified O
by O
the O
hras1 O
variable O
number O
of O
tandem O
repeat O
( O
vntr O
) O
locus O
. O

women O
who O
carry O
a O
mutation O
in O
the O
brca1 O
gene O
( O
on O
chromosome O
17q21 O
) O
, O
have O
an O
80 O
% O
risk O
of O
breast B-Disease
cancer I-Disease
and O
a O
40 O
% O
risk O
of O
ovarian B-Disease
cancer I-Disease
by O
the O
age O
of O
70 O
( O
ref O
. O

1 O
) O
. O

the O
hras1 O
variable O
number O
of O
tandem O
repeats O
( O
vntr O
) O
polymorphism O
, O
located O
1 O
kilobase O
( O
kb O
) O
downstream O
of O
the O
hras1 O
proto O
- O
oncogene O
( O
chromosome O
11p15 O
. O

5 O
) O
is O
one O
possible O
genetic O
modifier O
of O
cancer B-Disease
penetrance O
. O

individuals O
who O
have O
rare O
alleles O
of O
the O
vntr O
have O
an O
increased O
risk O
of O
certain O
types O
of O
cancers B-Disease
, O
including O
breast B-Disease
cancer I-Disease
( O
2 O
- O
4 O
) O
. O

to O
investigate O
whether O
the O
presence O
of O
rare O
hras1 O
alleles O
increases O
susceptibility O
to O
hereditary B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
, O
we O
have O
typed O
a O
panel O
of O
307 O
female O
brca1 O
carriers O
at O
this O
locus O
using O
a O
pcr O
- O
based O
technique O
. O

the O
risk O
for O
ovarian B-Disease
cancer I-Disease
was O
2 O
. O

the O
magnitude O
of O
the O
relative O
risk O
associated O
with O
a O
rare O
hras1 O
allele O
was O
not O
altered O
by O
adjusting O
for O
the O
other O
known O
risk O
factors O
for O
hereditary B-Disease
ovarian I-Disease
cancer I-Disease
( O
5 O
) O
. O

susceptibility O
to O
breast B-Disease
cancer I-Disease
did O
not O
appear O
to O
be O
affected O
by O
the O
presence O
of O
rare O
hras1 O
alleles O
. O

this O
study O
is O
the O
first O
to O
show O
the O
effect O
of O
a O
modifying O
gene O
on O
the O
penetrance O
of O
an O
inherited B-Disease
cancer I-Disease
syndrome I-Disease
a O
novel O
homeodomain O
- O
encoding O
gene O
is O
associated O
with O
a O
large O
cpg O
island O
interrupted O
by O
the O
myotonic B-Disease
dystrophy I-Disease
unstable O
( O
ctg O
) O
n O
repeat O
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
associated O
with O
a O
( O
ctg O
) O
n O
trinucleotide O
repeat O
expansion O
in O
the O
3 O
- O
untranslated O
region O
of O
a O
protein O
kinase O
- O
encoding O
gene O
, O
dmpk O
, O
which O
maps O
to O
chromosome O
19q13 O
. O

the O
dm B-Disease
region O
of O
chromosome O
19 O
is O
gene O
rich O
, O
and O
it O
is O
possible O
that O
the O
repeat O
expansion O
may O
lead O
to O
dysfunction O
of O
a O
number O
of O
transcription O
units O
in O
the O
vicinity O
, O
perhaps O
as O
a O
consequence O
of O
chromatin O
disruption O
. O

rt O
- O
pcr O
analysis O
shows O
that O
this O
gene O
, O
which O
we O
have O
called O
dm B-Disease
locus O
- O
associated O
homeodomain O
protein O
( O
dmahp O
) O
, O
is O
expressed O
in O
a O
number O
of O
human O
tissues O
, O
including O
skeletal O
muscle O
, O
heart O
and O
brain O
. O

germline O
mutations O
in O
the O
rb1 O
gene O
in O
patients O
with O
hereditary B-Disease
retinoblastoma I-Disease
. O

we O
have O
analyzed O
the O
27 O
exons O
and O
the O
promoter O
region O
of O
the O
rb1 O
gene O
in O
familial B-Disease
or I-Disease
sporadic I-Disease
bilateral I-Disease
retinoblastoma I-Disease
by O
using O
single O
- O
strand O
conformation O
polymorphism O
analysis O
. O

type B-Disease
ii I-Disease
human I-Disease
complement I-Disease
c2 I-Disease
deficiency I-Disease
. O

type B-Disease
ii I-Disease
complement I-Disease
protein I-Disease
c2 I-Disease
deficiency I-Disease
is O
characterized O
by O
a O
selective O
block O
in O
c2 O
secretion O
. O

the O
type O
ii O
c2 O
nan O
allele O
( O
c2q0 O
) O
is O
linked O
to O
two O
major O
histocompatibility O
haplotypes O
( O
mhc O
) O
that O
differ O
from O
the O
mhc O
of O
the O
more O
common O
type B-Disease
i I-Disease
c2 I-Disease
deficiency I-Disease
. O

to O
determine O
the O
molecular O
basis O
of O
type B-Disease
ii I-Disease
deficiency I-Disease
the O
two O
type O
ii O
c2q0 O
genes O
were O
isolated O
and O
transfected O
separately O
into O
l O
- O
cells O
. O

subsequent O
molecular O
biology O
, O
biosynthetic O
, O
and O
immunofluorescence O
studies O
demonstrated O
that O
c2 O
secretion O
is O
impaired O
in O
type B-Disease
ii I-Disease
c2 I-Disease
deficiency I-Disease
because O
of O
different O
missense O
mutations O
at O
highly O
conserved O
residues O
in O
each O
of O
the O
c2q0 O
alleles O
. O

defective O
dimerization O
of O
von B-Disease
willebrand I-Disease
factor O
subunits O
due O
to O
a O
cys O
- O
> O
arg O
mutation O
in O
type B-Disease
iid I-Disease
von I-Disease
willebrand I-Disease
disease I-Disease
. O

the O
same O
heterozygous O
t O
- O
> O
c O
transition O
at O
nt O
8567 O
of O
the O
von B-Disease
willebrand I-Disease
factor O
( O
vwf O
) O
transcript O
was O
found O
in O
two O
unrelated O
patients O
with O
type B-Disease
iid I-Disease
von I-Disease
willebrand I-Disease
disease I-Disease
, O
with O
no O
other O
apparent O
abnormality O
. O

we O
conclude O
that O
cys2010 O
is O
essential O
for O
normal O
dimerization O
of O
vwf O
subunits O
through O
disulfide O
bonding O
of O
carboxyl O
- O
terminal O
domains O
and O
that O
a O
heterozygous O
mutation O
in O
the O
corresponding O
codon O
is O
responsible O
for O
defective O
multimer O
formation O
in O
type B-Disease
iid I-Disease
von I-Disease
willebrand I-Disease
disease I-Disease
. O

. O

wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
protein O
, O
a O
novel O
effector O
for O
the O
gtpase O
cdc42hs O
, O
is O
implicated O
in O
actin O
polymerization O
. O

we O
have O
identified O
wasp O
, O
the O
protein O
that O
is O
defective O
in O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
( O
was B-Disease
) O
, O
as O
a O
novel O
effector O
for O
cdc42hs O
, O
but O
not O
for O
the O
other O
rho O
family O
members O
, O
rac O
and O
rho O
. O

thus O
, O
wasp O
provides O
a O
novel O
link O
between O
cdc42hs O
and O
the O
actin O
cytoskeleton O
, O
which O
suggests O
a O
molecular O
mechanism O
for O
many O
of O
the O
cellular O
abnormalities O
in O
was B-Disease
. O

x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
is O
a O
frequent O
cause O
of O
idiopathic O
addison B-Disease
' I-Disease
s I-Disease
disease I-Disease
in O
young O
adult O
male O
patients O
. O

x B-Disease
- I-Disease
linked I-Disease
adrenoleukodystrophy I-Disease
( O
ald B-Disease
) O
is O
a O
genetic B-Disease
disease I-Disease
associated O
with O
demyelination B-Disease
of I-Disease
the I-Disease
central I-Disease
nervous I-Disease
system I-Disease
, O
adrenal B-Disease
insufficiency I-Disease
, O
and O
accumulation O
of O
very O
long O
chain O
fatty O
acids O
in O
tissue O
and O
body O
fluids O
. O

ald B-Disease
is O
due O
to O
mutation O
of O
a O
gene O
located O
in O
xq28 O
that O
encodes O
a O
peroxisomal O
transporter O
protein O
of O
unknown O
function O
. O

the O
most O
common O
phenotype O
of O
ald B-Disease
is O
the O
cerebral O
form O
( O
45 O
% O
) O
that O
develops O
in O
boys O
between O
5 O
- O
12 O
yr O
. O

adrenomyeloneuropathy B-Disease
( O
amn B-Disease
) O
involves O
the O
spinal O
cord O
and O
peripheral O
nerves O
in O
young O
adults O
( O
35 O
% O
) O
. O

adrenal B-Disease
insufficiency I-Disease
( O
addisons B-Disease
disease I-Disease
) O
is O
frequently O
associated O
with O
amn B-Disease
or O
cerebral B-Disease
ald I-Disease
and O
may O
remain O
the O
only O
clinical O
expression O
of O
ald B-Disease
( O
8 O
% O
of O
cases O
) O
. O

the O
prevalence O
of O
ald B-Disease
among O
adults O
with O
addisons B-Disease
disease I-Disease
remains O
unknown O
. O

to O
evaluate O
this O
prevalence O
, O
we O
performed O
biochemical O
analysis O
of O
very O
long O
chain O
fatty O
acids O
in O
14 O
male O
patients O
( O
age O
ranging O
from O
12 O
- O
45 O
yr O
at O
diagnosis O
) O
previously O
diagnosed O
as O
having O
primary O
idiopathic O
adrenocortical B-Disease
insufficiency I-Disease
. O

by O
electrophysiological O
tests O
and O
magnetic O
resonance O
imaging O
it O
was O
determined O
that O
two O
patients O
had O
cerebral B-Disease
ald I-Disease
, O
one O
had O
adrenomyeloneuropathy B-Disease
with O
cerebral O
involvement O
, O
and O
two O
had O
preclinical O
amn B-Disease
. O

our O
data O
support O
the O
hypothesis O
that O
ald B-Disease
is O
a O
frequent O
cause O
of O
idiopathic O
addisons B-Disease
disease I-Disease
in O
children O
and O
adults O
. O

. O

tumor B-Disease
suppression O
and O
apoptosis O
of O
human O
prostate B-Disease
carcinoma I-Disease
mediated O
by O
a O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
. O

prostate B-Disease
cancer I-Disease
is O
the O
second O
leading O
cause O
of O
male O
cancer B-Disease
deaths O
in O
the O
united O
states O
. O

prostate O
secretory O
epithelial O
cells O
and O
androgen O
- O
dependent O
prostate B-Disease
carcinomas I-Disease
undergo O
apoptosis O
in O
response O
to O
androgen O
deprivation O
and O
, O
furthermore O
, O
most O
prostate B-Disease
carcinomas I-Disease
become O
androgen O
independent O
and O
refractory O
to O
further O
therapeutic O
manipulations O
during O
disease O
progression O
. O

we O
report O
the O
functional O
definition O
of O
a O
novel O
genetic O
locus O
within O
human O
chromosome O
10pter O
- O
q11 O
that O
mediates O
both O
in O
vivo O
tumor O
suppression O
and O
in O
vitro O
apoptosis O
of O
prostatic B-Disease
adenocarcinoma I-Disease
cells O
. O

a O
defined O
fragment O
of O
human O
chromosome O
10 O
was O
transferred O
via O
microcell O
fusion O
into O
a O
prostate B-Disease
adenocarcinoma I-Disease
cell O
line O
. O

these O
data O
functionally O
define O
a O
novel O
genetic O
locus O
, O
designated O
pac1 O
, O
for O
prostate O
adenocarcinoma O
1 O
, O
involved O
in O
tumor O
suppression O
of O
human O
prostate B-Disease
carcinoma I-Disease
and O
furthermore O
strongly O
suggest O
that O
the O
cell O
death O
pathway O
can O
be O
functionally O
restored O
in O
prostatic B-Disease
adenocarcinoma I-Disease
. O

. O

low O
incidence O
of O
brca2 O
mutations O
in O
breast B-Disease
carcinoma I-Disease
and O
other O
cancers B-Disease
. O

inherited O
mutant O
alleles O
of O
familial O
tumour B-Disease
suppressor O
genes O
predispose O
individuals O
to O
particular O
types O
of O
cancer B-Disease
. O

in O
addition O
to O
an O
involvement O
in O
inherited O
susceptibility O
to O
cancer B-Disease
, O
these O
tumour B-Disease
suppressor O
genes O
are O
targets O
for O
somatic O
mutations O
in O
sporadic B-Disease
cancers I-Disease
of O
the O
same O
type O
found O
in O
the O
familial O
forms O
. O

an O
exception O
is O
brca1 O
, O
which O
contributes O
to O
a O
significant O
fraction O
of O
familial B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
, O
but O
undergoes O
mutation O
at O
very O
low O
rates O
in O
sporadic B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
. O

this O
finding O
suggests O
that O
other O
genes O
may O
be O
the O
principal O
targets O
for O
somatic O
mutation O
in O
breast B-Disease
carcinoma I-Disease
. O

a O
second O
, O
recently O
identified O
familial B-Disease
breast I-Disease
cancer I-Disease
gene O
, O
brca2 O
( O
refs O
5 O
- O
8 O
) O
, O
accounts O
for O
a O
proportion O
of O
breast B-Disease
cancer I-Disease
roughly O
equal O
to O
brca1 O
. O

like O
brca1 O
, O
brca2 O
behaves O
as O
a O
dominantly O
inherited O
tumour B-Disease
suppressor O
gene O
. O

individuals O
who O
inherit O
one O
mutant O
allele O
are O
at O
increased O
risk O
for O
breast B-Disease
cancer I-Disease
, O
and O
the O
tumours B-Disease
they O
develop O
lose O
the O
wild O
- O
type O
allele O
by O
heterozygous O
deletion O
. O

here O
we O
investigate O
the O
rate O
of O
brca2 O
mutation O
in O
sporadic B-Disease
breast I-Disease
cancers I-Disease
and O
in O
a O
set O
of O
cell O
lines O
that O
represent O
twelve O
other O
tumour B-Disease
types O
. O

surprisingly O
, O
mutations O
in O
brca2 O
are O
infrequent O
in O
cancers B-Disease
including O
breast B-Disease
carcinoma I-Disease
. O

however O
, O
a O
probable O
germline O
mutation O
in O
a O
pancreatic B-Disease
tumour I-Disease
cell O
line O
suggests O
a O
role O
for O
brca2 O
in O
susceptibility O
to O
pancreatic B-Disease
cancer I-Disease
. O

. O

founding O
brca1 O
mutations O
in O
hereditary B-Disease
breast I-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
in O
southern O
sweden O
. O

nine O
different O
germ O
- O
line O
mutations O
in O
the O
brca1 O
breast B-Disease
and I-Disease
ovarian I-Disease
cancer I-Disease
susceptibility O
gene O
were O
identified O
in O
15 O
of O
47 O
kindreds O
from O
southern O
sweden O
, O
by O
use O
of O
sscp O
and O
heteroduplex O
analysis O
of O
all O
exons O
and O
flanking O
intron O
region O
and O
by O
a O
protein O
- O
truncation O
test O
for O
exon O
11 O
, O
followed O
by O
direct O
sequencing O
. O

eleven O
of O
the O
15 O
kindreds O
manifesting O
brca1 O
mutations O
were O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
families O
, O
several O
of O
them O
with O
a O
predominant O
ovarian B-Disease
cancer I-Disease
phenotype O
. O

the O
set O
of O
32 O
families O
in O
which O
no O
brca1 O
alterations O
were O
detected O
included O
1 O
breast B-Disease
- I-Disease
ovarian I-Disease
cancer I-Disease
kindred O
manifesting O
clear O
linkage O
to O
the O
brca1 O
region O
and O
loss O
of O
the O
wild O
- O
type O
chromosome O
in O
associated O
tumors B-Disease
. O

other O
tumor B-Disease
types O
found O
in O
brca1 O
mutation O
/ O
haplotype O
carriers O
included O
prostatic B-Disease
, I-Disease
pancreas I-Disease
, I-Disease
skin I-Disease
, I-Disease
and I-Disease
lung I-Disease
cancer I-Disease
, O
a O
malignant B-Disease
melanoma I-Disease
, O
an O
oligodendroglioma B-Disease
, O
and O
a O
carcinosarcoma B-Disease
. O

in O
all O
, O
12 O
of O
16 O
kindreds O
manifesting O
brca1 O
mutation O
or O
linkage O
contained O
ovarian B-Disease
cancer I-Disease
, O
as O
compared O
with O
only O
6 O
of O
the O
remaining O
31 O
families O
( O
p O
< O
. O

1 O
) O
. O

the O
present O
study O
confirms O
the O
involvement O
of O
brca1 O
in O
disease O
predisposition O
for O
a O
subset O
of O
hereditary B-Disease
breast I-Disease
cancer I-Disease
families O
often O
characterized O
by O
ovarian B-Disease
cancers I-Disease
. O

ukcccr O
familial O
ovarian B-Disease
cancer I-Disease
study O
group O
. O

germ O
- O
line O
mutations O
of O
the O
brca1 O
gene O
are O
responsible O
for O
a O
substantial O
proportion O
of O
families O
with O
multiple O
cases O
of O
early O
- O
onset O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
. O

we O
have O
developed O
a O
multiplex O
heteroduplex O
analysis O
that O
is O
designed O
to O
analyze O
one O
- O
quarter O
of O
the O
coding O
sequence O
in O
a O
single O
- O
step O
screening O
procedure O
and O
that O
will O
detect O
approximately O
50 O
% O
of O
all O
brca1 O
mutations O
so O
far O
reported O
in O
breast B-Disease
/ I-Disease
ovarian I-Disease
cancer I-Disease
families O
. O

we O
have O
used O
this O
technique O
to O
analyze O
brca1 O
in O
162 O
families O
with O
a O
history O
of O
breast B-Disease
and I-Disease
/ I-Disease
or I-Disease
ovarian I-Disease
cancer I-Disease
and O
identified O
12 O
distinct O
mutations O
in O
35 O
families O
. O

. O

a O
previously O
undescribed O
mutation O
within O
the O
tetramerisation O
domain O
of O
tp53 O
in O
a O
family O
with O
li B-Disease
- I-Disease
fraumeni I-Disease
syndrome I-Disease
. O

we O
report O
details O
of O
a O
family O
with O
classic O
li B-Disease
- I-Disease
fraumeni I-Disease
syndrome I-Disease
in O
which O
there O
is O
a O
mutation O
in O
codon O
344 O
of O
the O
tumour B-Disease
suppressor O
gene O
tp53 O
. O

this O
is O
the O
first O
report O
of O
a O
mutation O
at O
this O
residue O
in O
either O
sporadic B-Disease
tumours I-Disease
or O
in O
the O
germline O
and O
the O
first O
report O
of O
a O
germline O
mutation O
within O
the O
tetramerisation O
domain O
. O

the O
family O
does O
not O
appear O
to O
be O
remarkable O
in O
the O
spectrum O
of O
tumours B-Disease
, O
and O
there O
is O
loss O
of O
the O
wild O
- O
type O
allele O
in O
a O
leiomyosarcoma B-Disease
from O
the O
proband O
. O

a O
cell O
line O
has O
been O
established O
from O
the O
tumour B-Disease
of O
the O
proband O
and O
cytogenetic O
and O
molecular O
studies O
carried O
out O
, O
providing O
an O
extensive O
analysis O
in O
this O
family O
. O

. O

the O
spectrum O
of O
rb1 O
germ O
- O
line O
mutations O
in O
hereditary B-Disease
retinoblastoma I-Disease
. O

we O
have O
searched O
for O
germ O
- O
line O
rb1 O
mutations O
in O
119 O
patients O
with O
hereditary B-Disease
retinoblastoma I-Disease
. O

no O
correlation O
between O
the O
location O
of O
frameshift O
or O
nonsense O
mutations O
and O
phenotypic O
features O
, O
including O
age O
at O
diagnosis O
, O
the O
number O
of O
tumor B-Disease
foci O
, O
and O
manifestation O
of O
nonocular B-Disease
tumors I-Disease
was O
observed O
. O

. O

phenotypic O
characterization O
of O
individuals O
with O
30 O
- O
40 O
cag O
repeats O
in O
the O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
gene O
reveals O
hd B-Disease
cases O
with O
36 O
repeats O
and O
apparently O
normal O
elderly O
individuals O
with O
36 O
- O
39 O
repeats O
. O

abnormal O
cag O
expansions O
in O
the O
it O
- O
15 O
gene O
are O
associated O
with O
huntington B-Disease
disease I-Disease
( O
hd B-Disease
) O
. O

in O
the O
diagnostic O
setting O
it O
is O
necessary O
to O
define O
the O
limits O
of O
the O
cag O
size O
ranges O
on O
normal O
and O
hd B-Disease
- O
associated O
chromosomes O
. O

seven O
hd B-Disease
patients O
had O
36 O
repeats O
, O
which O
confirms O
that O
this O
allele O
is O
associated O
with O
disease O
. O

individuals O
without O
apparent O
symptoms O
or O
signs O
of O
hd B-Disease
were O
found O
at O
36 O
repeats O
( O
aged O
74 O
, O
78 O
, O
79 O
, O
and O
87 O
years O
) O
, O
37 O
repeats O
( O
aged O
69 O
years O
) O
, O
38 O
repeats O
( O
aged O
69 O
and O
90 O
years O
) O
, O
and O
39 O
repeats O
( O
aged O
67 O
, O
90 O
, O
and O
95 O
years O
) O
. O

the O
detailed O
case O
histories O
of O
an O
exceptional O
case O
from O
this O
series O
will O
be O
presented O
a O
95 O
- O
year O
- O
old O
man O
with O
39 O
repeats O
who O
did O
not O
have O
classical O
features O
of O
hd B-Disease
. O

the O
apparently O
healthy O
survival O
into O
old O
age O
of O
some O
individuals O
with O
36 O
- O
39 O
repeats O
suggests O
that O
the O
hd B-Disease
mutation O
may O
not O
always O
be O
fully O
penetrant O
. O

. O

identification O
and O
expression O
of O
eight O
novel O
mutations O
among O
non O
- O
jewish O
patients O
with O
canavan B-Disease
disease I-Disease
. O

canavan B-Disease
disease I-Disease
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
that O
is O
caused O
by O
the O
deficiency B-Disease
of I-Disease
aspartoacylase I-Disease
( O
aspa O
) O
. O

the O
majority O
of O
patients O
with O
canavan B-Disease
disease I-Disease
are O
from O
an O
ashkenazi O
jewish O
background O
. O

the O
current O
study O
was O
aimed O
at O
finding O
the O
molecular O
basis O
of O
canavan B-Disease
disease I-Disease
in O
25 O
independent O
patients O
of O
non O
- O
jewish O
background O
. O

the O
homozygous O
32 O
deltat O
deletion O
was O
identified O
in O
the O
only O
known O
patient O
of O
african O
- O
american O
origin O
with O
canavan B-Disease
disease I-Disease
. O

in O
vitro O
expression O
of O
mutant O
cdna O
clones O
demonstrated O
that O
all O
of O
these O
mutations O
led O
to O
a O
deficiency B-Disease
of I-Disease
aspa I-Disease
and O
should O
therefore O
result O
in O
canavan B-Disease
disease I-Disease
. O

. O

identification O
and O
chromosomal O
localization O
of O
atm O
, O
the O
mouse O
homolog O
of O
the O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
gene O
. O

atm O
, O
the O
mouse O
homolog O
of O
the O
human O
atm O
gene O
defective O
in O
ataxia B-Disease
- I-Disease
telangiectasia I-Disease
( O
a B-Disease
- I-Disease
t I-Disease
) O
, O
has O
been O
identified O
. O

the O
mouse O
homolog O
of O
the O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
protein O
( O
wasp O
) O
gene O
is O
highly O
conserved O
and O
maps O
near O
the O
scurfy O
( O
sf O
) O
mutation O
on O
the O
x O
chromosome O
. O

the O
mouse O
wasp O
gene O
, O
the O
homolog O
of O
the O
gene O
mutated O
in O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
, O
has O
been O
isolated O
and O
sequenced O
. O

the O
predicted O
amino O
acid O
sequence O
is O
86 O
% O
identical O
to O
the O
human O
wasp O
sequence O
. O

this O
localization O
makes O
wasp O
a O
candidate O
for O
involvement O
in O
scurfy O
, O
a O
t O
cell O
- O
mediated O
fatal B-Disease
lymphoreticular I-Disease
disease I-Disease
of O
mice O
that O
has O
previously O
been O
proposed O
as O
a O
mouse O
homolog O
of O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
. O

colchicine O
in O
breast O
milk O
of O
patients O
with O
familial B-Disease
mediterranean I-Disease
fever I-Disease
. O

to O
clarify O
whether O
colchicine O
is O
excreted O
in O
breast O
milk O
, O
and O
to O
compare O
its O
concentrations O
in O
the O
serum O
and O
breast O
milk O
of O
lactating O
women O
who O
have O
familial B-Disease
mediterranean I-Disease
fever I-Disease
( O
fmf B-Disease
) O
. O

the O
study O
evaluated O
4 O
patients O
with O
fmf B-Disease
who O
had O
been O
taking O
colchicine O
on O
a O
long O
- O
term O
basis O
. O

furthermore O
, O
based O
on O
our O
clinical O
experience O
, O
nursing O
appears O
to O
be O
safe O
for O
lactating O
women O
with O
fmf B-Disease
who O
continue O
to O
take O
colchicine O
. O

abnormal O
myotonic B-Disease
dystrophy I-Disease
protein O
kinase O
levels O
produce O
only O
mild O
myopathy B-Disease
in O
mice O
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
commonly O
associated O
with O
ctg O
repeat O
expansions O
within O
the O
gene O
for O
dm O
- O
protein O
kinase O
( O
dmpk O
) O
. O

nullizygous O
( O
- O
/ O
- O
) O
mice O
showed O
only O
inconsistent O
and O
minor O
size O
changes O
in O
head O
and O
neck O
muscle O
fibres O
at O
older O
age O
, O
animals O
with O
the O
highest O
dmpk O
transgene O
expression O
showed O
hypertrophic B-Disease
cardiomyopathy I-Disease
and O
enhanced O
neonatal O
mortality O
. O

however O
, O
both O
models O
lack O
other O
frequent O
dm B-Disease
symptoms O
including O
the O
fibre O
- O
type O
dependent O
atrophy B-Disease
, O
myotonia B-Disease
, O
cataract B-Disease
and O
male B-Disease
- I-Disease
infertility I-Disease
. O

mice O
lacking O
the O
myotonic B-Disease
dystrophy I-Disease
protein O
kinase O
develop O
a O
late O
onset O
progressive O
myopathy B-Disease
. O

myotonic B-Disease
dystrophy I-Disease
( O
dm B-Disease
) O
is O
an O
autosomal B-Disease
dominant I-Disease
disorder I-Disease
resulting O
from O
the O
expansion O
of O
a O
ctg O
repeat O
in O
the O
3 O
untranslated O
region O
of O
a O
putative O
protein O
kinase O
( O
dmpk O
) O
. O

to O
elucidate O
the O
role O
of O
dmpk O
in O
dm B-Disease
pathogenesis O
we O
have O
developed O
dmpk B-Disease
deficient I-Disease
( O
dmpk O
- O
/ O
- O
) O
mice O
. O

dmpk O
- O
/ O
- O
mice O
develop O
a O
late O
- O
onset O
, O
progressive B-Disease
skeletal I-Disease
myopathy I-Disease
that O
shares O
some O
pathological O
features O
with O
dm B-Disease
. O

muscles O
from O
mature O
mice O
show O
variation O
in O
fibre O
size O
, O
increased O
fibre B-Disease
degeneration I-Disease
and O
fibrosis B-Disease
. O

our O
results O
indicate O
that O
dmpk O
may O
be O
necessary O
for O
the O
maintenance O
of O
skeletal O
muscle O
structure O
and O
function O
and O
suggest O
that O
a O
decrease O
in O
dmpk O
levels O
may O
contribute O
to O
dm B-Disease
pathology O
. O

. O

the O
tumor B-Disease
suppressor O
gene O
brca1 O
is O
required O
for O
embryonic O
cellular O
proliferation O
in O
the O
mouse O
. O

mutations O
of O
the O
brca1 O
gone O
in O
humans O
are O
associated O
with O
predisposition O
to O
breast B-Disease
and I-Disease
ovarian I-Disease
cancers I-Disease
. O

we O
show O
here O
that O
brca1 O
+ O
/ O
- O
mice O
are O
normal O
and O
fertile O
and O
lack O
tumors B-Disease
by O
age O
eleven O
months O
. O

increased O
coronary B-Disease
heart I-Disease
disease I-Disease
in O
japanese O
- O
american O
men O
with O
mutation O
in O
the O
cholesteryl O
ester O
transfer O
protein O
gene O
despite O
increased O
hdl O
levels O
. O

plasma O
high O
density O
lipoprotein O
( O
hdl O
) O
levels O
are O
strongly O
genetically O
determined O
and O
show O
a O
general O
inverse O
relationship O
with O
coronary B-Disease
heart I-Disease
disease I-Disease
( O
chd B-Disease
) O
. O

however O
, O
the O
overall O
prevalence O
of O
definite O
chd B-Disease
was O
21 O
% O
in O
men O
with O
mutations O
and O
16 O
% O
in O
men O
without O
mutations O
. O

the O
relative O
risk O
( O
rr O
) O
of O
chd B-Disease
was O
1 O
. O

43 O
in O
men O
with O
mutations O
( O
p O
< O
. O

5 O
) O
; O
after O
adjustment O
for O
chd B-Disease
risk O
factors O
, O
the O
rr O
was O
1 O
. O

increased O
chd B-Disease
in O
men O
with O
mutations O
was O
primarily O
observed O
for O
hdl O
chol O
41 O
- O
60 O
mg O
/ O
dl O
; O
for O
hdl O
chol O
> O
60 O
mg O
/ O
dl O
men O
with O
and O
without O
mutations O
had O
low O
chd B-Disease
prevalence O
. O

thus O
, O
genetic O
cetp B-Disease
deficiency I-Disease
appears O
to O
be O
an O
independent O
risk O
factor O
for O
chd B-Disease
, O
primarily O
due O
to O
increased O
chd B-Disease
prevalence O
in O
men O
with O
the O
d442g O
mutation O
and O
hdl O
cholesterol O
between O
41 O
and O
60 O
mg O
/ O
dl O
. O

the O
rb1 O
gene O
has O
been O
implicated O
with O
retinoblastoma B-Disease
and O
is O
located O
on O
human O
chromosome O
( O
chr O
) O
13q14 O
. O

tuber B-Plant
melanosporum I-Plant
: O
mat O
type O
distribution O
in O
a O
natural O
plantation O
and O
dynamic O
of O
strain O
of O
different O
mating O
type O
on O
the O
root O
of O
nursery O
- O
inoculate O
host O
plant O
. O

in O
light O
of O
the O
recent O
finding O
that O
tuber B-Plant
melanosporum I-Plant
, O
the O
ectomycorrhizal O
ascomycete O
that O
produce O
the O
most O
highly O
prize O
black O
truffle O
, O
be O
a O
heterothallic O
specie O
, O
monitor O
the O
spatial O
distribution O
of O
strain O
with O
opposite O
mating O
type O
( O
mat O
) O
in O
a O
natural O
truffle O
ground O
and O
follow O
strain O
dynamic O
in O
artificially O
inoculate O
host O
plant O
grow O
under O
control O
condition O
. O

the O
present O
study O
deepen O
understanding O
of O
the O
vegetative O
and O
sexual O
propagation O
mode O
of O
t. B-Plant
melanosporum I-Plant
. O

sgt1 O
contribute O
to O
coronatine O
signaling O
and O
pseudomonas O
syringae O
pv. O
tomato B-Plant
disease O
symptom O
development O
in O
tomato B-Plant
and O
arabidopsis O
. O

pseudomona O
syringae O
pv. O
tomato B-Plant
dc3000 O
( O
pst O
dc3000 O
) O
cause O
an O
economically O
important O
bacterial O
speck O
disease O
on O
tomato B-Plant
and O
produce O
symptom O
with O
necrotic O
lesion O
surround O
by O
chlorosis O
. O

in O
this O
study O
, O
take O
advantage O
of O
a O
chlorotic O
phenotype O
elicit O
by O
cor O
on O
nicotiana B-Plant
benthamiana I-Plant
leaf O
and O
virus O
- O
induce O
gene O
silencing O
( O
vigs O
) O
as O
a O
rapid O
reverse O
genetic O
screening O
tool O
and O
identify O
a O
role O
for O
sgt1 O
( O
suppressor O
of O
g2 O
allele O
of O
skp1 O
) O
in O
cor O
- O
induce O
chlorosis O
. O

silence O
of O
sgt1 O
in O
tomato B-Plant
result O
in O
reduction O
of O
disease O
- O
associate O
symptom O
( O
cell O
death O
and O
chlorosis O
) O
, O
suggest O
a O
molecular O
connection O
between O
cor O
- O
induce O
chlorosis O
and O
cell O
death O
. O

take O
together O
, O
result O
demonstrate O
that O
sgt1/sgt1b O
be O
require O
for O
cor O
- O
induce O
chlorosis O
and O
subsequent O
necrotic O
disease O
development O
in O
tomato B-Plant
and O
arabidopsis O
. O

oshma3 O
, O
a O
p1b O
- O
type O
of O
atpase O
affect O
root O
- O
to O
- O
shoot O
cadmium O
translocation O
in O
rice B-Plant
by O
mediate O
efflux O
into O
vacuole O
. O

the O
cadmium O
( O
cd O
) O
over O
- O
accumulate O
rice B-Plant
( O
oryza B-Plant
sativa I-Plant
) O
cv O
cho O
- O
ko O
- O
koku O
be O
previously O
show O
to O
have O
an O
enhanced O
rate O
of O
root O
- O
to O
- O
shoot O
cd O
translocation O
. O

propose O
that O
the O
root O
cell O
cytoplasm O
of O
cd O
- O
overaccumulat O
rice B-Plant
plant O
have O
more O
cd O
available O
for O
loading O
into O
the O
xylem O
as O
a O
result O
of O
the O
lack O
of O
oshma3-mediated O
transportation O
of O
cd O
to O
the O
vacuole O
. O

these O
datum O
demonstrate O
the O
importance O
of O
vacuolar O
sequestration O
for O
cd O
accumulation O
in O
rice B-Plant
. O

spatial O
distribution O
of O
arsenic O
and O
temporal O
variation O
of O
concentration O
in O
rice B-Plant
. O

in O
order O
to O
gain O
insight O
into O
the O
transport O
and O
distribution O
of O
arsenic O
( O
as O
) O
in O
intact O
rice B-Plant
( O
oryza B-Plant
sativa I-Plant
) O
plant O
and O
unloading O
into O
the O
rice B-Plant
grain O
, O
investigate O
the O
spatial O
distribution O
of O
as O
and O
the O
temporal O
variation O
of O
as O
concentration O
in O
whole O
rice B-Plant
plant O
at O
different O
growth O
stage O
. O

moreover O
, O
node O
appear O
to O
serve O
as O
a O
check O
- O
point O
in O
as O
distribution O
in O
rice B-Plant
shoot O
. O

intra O
- O
ring O
delta(13 O
) O
c O
be O
measure O
in O
-30 O
to O
60-mum O
- O
thick O
slice O
in O
eight O
oak B-Plant
tree O
( O
quercus B-Plant
petraea I-Plant
) O
. O

resistance O
and O
recovery O
of O
soil O
microbial O
community O
in O
the O
face O
of O
alliaria B-Plant
petiolata I-Plant
invasion O
. O

in O
soil O
community O
sample O
from O
site O
along O
a O
gradient O
of O
invasion O
history O
with O
alliaria B-Plant
petiolata I-Plant
, O
microbial O
richness O
tend O
to O
decline O
, O
but O
the O
community O
's O
resistance O
to O
a. B-Plant
petiolata I-Plant
's O
effect O
generally O
increase O
with O
increase O
history O
of O
invasion O
. O

this O
may O
be O
because O
of O
evolutionary O
change O
in O
the O
a. B-Plant
petiolata I-Plant
population O
, O
which O
tend O
to O
reduce O
investment O
to O
allelopathic O
compound O
over O
time O
. O

analyse O
the O
precise O
kinetic O
and O
physiological O
control O
of O
petiole O
elongation O
response O
to O
shade O
and O
submergence O
in O
the O
flood O
- O
tolerant O
specie O
rumex B-Plant
palustris I-Plant
. O

the O
magnitude O
of O
the O
' O
ionic O
effect O
' O
be O
link O
with O
vessel O
and O
pit O
dimension O
in O
20 O
angiosperm O
specie O
cover O
13 O
family O
include O
six O
lauraceae B-Plant
specie O
. O

plant O
from O
this O
genus O
produce O
toxic O
alkaloid O
and O
cardiac O
glycosid O
g O
- O
strophanthin O
( O
syn O
ouabain B-Plant
) O
, O
k O
- O
strophanthin O
, O
and O
e O
- O
strophanthin O
. O

some O
of O
the O
chemical O
in O
the O
plant O
be O
use O
to O
produce O
the O
drug O
ouabain B-Plant
, O
which O
be O
take O
as O
a O
cardiac O
stimulant O
to O
treat O
heart O
failure O
and O
sometimes O
g O
- O
strophanthin O
be O
advocate O
as O
an O
alternative O
treatment O
to O
more O
contemporary O
practice O
. O

the O
effect O
be O
similar O
to O
that O
of O
the O
drug O
digoxin O
, O
which O
be O
produce O
from O
digitalis B-Plant
purpurea I-Plant
. O

formerly O
include O
in O
genusstrophanthus O
aambe O
= O
papuechites B-Plant
aambe I-Plant
ginkgo B-Plant
biloba I-Plant
, O
commonly O
know O
as O
ginkgo O
or O
gingko O
( O
both O
pronounce O
) O
, O
also O
know O
as O
the O
maidenhair B-Plant
tree I-Plant
, O
be O
the O
only O
living O
specie O
in O
the O
division O
ginkgophyta O
, O
all O
other O
be O
extinct O
. O

dipsacus B-Plant
fullonum I-Plant
, O
syn O
dipsacus B-Plant
sylvestris I-Plant
, O
be O
a O
species O
of O
flower O
plant O
know O
by O
the O
common O
name O
wild B-Plant
teasel I-Plant
or O
full B-Plant
's I-Plant
teasel I-Plant
, O
although O
the O
latter O
name O
be O
usually O
apply O
to O
the O
cultivate O
species O
dipsacus B-Plant
sativus I-Plant
. O

the O
inflorescence O
be O
a O
cylindrical O
array O
of O
lavender B-Plant
flower O
which O
dry O
to O
a O
cone O
of O
spine O
- O
tip O
hard O
bract O
. O

bulbophyllum B-Plant
absconditum I-Plant
, O
know O
as O
the O
' O
hidden O
bulbophyllum O
, O
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

betula B-Plant
michauxii I-Plant
, O
newfoundland B-Plant
dwarf I-Plant
birch I-Plant
, O
be O
a O
species O
of O
birch B-Plant
which O
be O
native O
to O
newfoundland O
from O
which O
-PRON- O
get O
introduce O
to O
nova O
scotia O
and O
quebec O
. O

plinia B-Plant
cauliflora I-Plant
, O
the O
brazilian B-Plant
grapetree I-Plant
, O
jaboticaba B-Plant
or O
jabuticaba O
, O
be O
a O
tree O
in O
the O
family O
myrtaceae O
, O
native O
to O
minas O
gerais O
, O
goiÃ¡s O
and O
sÃ£o O
paulo O
state O
in O
brazil O
. O

three O
specie O
( O
g. B-Plant
odorata I-Plant
, O
g. B-Plant
scabra I-Plant
, O
g. B-Plant
speciosa I-Plant
) O
be O
know O
in O
cultivation O
. O

guettarda B-Plant
argentea I-Plant
provide O
edible O
fruit O
. O

the O
type O
specie O
for O
the O
genus O
be O
guettarda B-Plant
speciosa I-Plant
. O

fir O
be O
most O
closely O
related O
to O
the O
genus O
cedrus O
( O
cedar B-Plant
) O
. O

douglas B-Plant
fir I-Plant
be O
not O
TRUE O
fir O
, O
be O
of O
the O
genus O
pseudotsuga O
. O

fir O
can O
be O
distinguish O
from O
other O
member O
of O
the O
pine O
family O
by O
the O
way O
in O
which O
needle O
- O
like O
leaf O
be O
attach O
singly O
to O
the O
branch O
with O
a O
base O
resemble O
a O
suction O
cup O
, O
and O
by O
-PRON- O
cone O
, O
which O
, O
like O
those O
of O
atlas B-Plant
cedar I-Plant
( O
cedrus O
) O
, O
stand O
upright O
on O
the O
branch O
like O
candle O
and O
disintegrate O
at O
maturity O
. O

cryptarrhena O
be O
a O
genus O
of O
orchid B-Plant
( O
family O
orchidaceae O
) O
. O

bonnemaisoniaceae O
be O
a O
family O
of O
red O
algae B-Plant
in O
the O
order O
bonnemaisoniales O
. O

kelloggia O
be O
a O
plant O
genus O
in O
the O
bedstraw B-Plant
and O
madder O
family O
rubiaceae O
. O

be O
know O
by O
the O
native O
hawaiians O
as O
hau B-Plant
kuahiwi I-Plant
which O
mean O
mountain O
hibiscus O
. O

mirabilis B-Plant
longiflora I-Plant
, O
sweet B-Plant
four I-Plant
o'clock I-Plant
, O
be O
a O
species O
of O
flower O
plant O
native O
to O
the O
southwestern O
united O
states O
from O
arizona O
to O
texas O
and O
northern O
mexico O
. O

specie O
include O
gomesa B-Plant
radican I-Plant
. O

when O
carl O
linnaeus O
name O
this O
genus O
in O
1763 O
, O
include O
in O
this O
genus O
all O
the O
epiphytic O
orchid B-Plant
know O
to O
. O

although O
few O
of O
these O
orchid B-Plant
be O
still O
include O
in O
the O
genus O
epidendrum O
, O
some O
specie O
of O
epidendrum O
be O
nevertheless O
not O
epiphytic O
. O

lemon B-Plant
balm O
( O
melissa B-Plant
officinali I-Plant
) O
, O
balm O
, O
common B-Plant
balm I-Plant
, O
or O
balm O
mint B-Plant
, O
be O
a O
perennial O
herbaceous O
plant O
in O
the O
mint O
family O
lamiaceae O
and O
native O
to O
south O
- O
central O
europe O
, O
the O
mediterranean O
basin O
, O
iran O
, O
and O
central O
asia O
, O
but O
now O
naturalize O
in O
the O
americas O
and O
elsewhere O
. O

grow O
to O
a O
maximum O
height O
of O
70â€“150 O
cm O
( O
28â€“59 O
in O
) O
. O

the O
leaf O
have O
a O
mild O
lemon B-Plant
scent O
similar O
to O
mint B-Plant
. O

the O
tea B-Plant
of O
lemon B-Plant
balm O
, O
the O
essential O
oil O
, O
and O
the O
extract O
be O
use O
in O
traditional O
and O
alternative O
medicine O
, O
include O
aromatherapy O
. O

the O
plant O
have O
be O
cultivate O
at O
least O
since O
the O
16th O
century O
, O
but O
research O
be O
still O
be O
conduct O
to O
establish O
the O
safety O
and O
effect O
of O
lemon B-Plant
balm O
. O

crobylanthe B-Plant
pellacalyx I-Plant
, O
which O
be O
endemic O
to O
sarawak O
. O

asphodelus B-Plant
aestivus I-Plant
, O
the O
summer O
asphodel B-Plant
, O
be O
a O
species O
of O
asphodel B-Plant
, O
a O
common O
western O
mediterranean O
geophyte O
with O
a O
short O
vertical O
rhizome O
and O
basal O
leaf O
. O

there O
have O
be O
a O
lot O
of O
confusion O
over O
the O
nomenclature O
and O
taxonomy O
of O
the O
specie O
, O
especially O
in O
confusion O
with O
asphodelus B-Plant
ramosus I-Plant
. O

satyrium O
be O
a O
genus O
of O
orchid B-Plant
. O

elymus O
be O
a O
genus O
of O
perennial O
plant O
with O
approximately O
150 O
specie O
in O
the O
grass O
family O
, O
relate O
to O
rye B-Plant
, O
wheat B-Plant
, O
and O
other O
widely O
grow O
cereal O
grain O
. O

common O
name O
include O
couch B-Plant
grass I-Plant
, O
wildrye B-Plant
and O
wheatgrass B-Plant
. O

many O
specie O
once O
consider O
member O
of O
elymus O
be O
now O
regard O
as O
better O
suit O
to O
other O
genera O
: O
agropyron O
, O
anthosachne O
, O
brachypodium O
, O
cenchrus O
, O
crithopsis O
, O
heteranthelium O
, O
jouvea O
, O
kengyilia O
, O
leymus O
, O
psathyrostachys O
, O
stenostachys O
, O
taeniatherum O
, O
thinopyrum O
etc O
. O

the O
following O
specie O
be O
recognise O
by O
the O
plant O
list O
: O
moreover O
, O
scleroderma O
citrinum O
have O
much O
firm O
flesh O
and O
a O
dark O
gleba O
( O
interior O
) O
much O
earlier O
in O
development O
than O
puffball B-Plant
. O

pinellia B-Plant
ternata I-Plant
( O
chinese O
: O
, O
japanese O
: O
) O
, O
crow B-Plant
- I-Plant
dipper I-Plant
, O
be O
a O
plant O
native O
to O
china O
, O
japan O
, O
and O
korea O
, O
but O
also O
grow O
as O
an O
invasive O
weed O
in O
part O
of O
europe O
( O
austria O
, O
germany O
) O
and O
north O
america O
( O
california O
, O
ontario O
, O
northeastern O
united O
states O
) O
. O

general O
common O
name O
include O
indian B-Plant
mallow I-Plant
and O
velvetleaf B-Plant
in O
russian O
, O
ornamental O
variety O
be O
commonly O
know O
as O
the O
room B-Plant
maple I-Plant
. O

the O
generic O
name O
be O
derive O
from O
the O
latin O
word O
moru O
mulberry B-Plant
, O
from O
the O
appearance O
of O
the O
fruit O
, O
and O
indica O
, O
mean O
of O
india O
. O

grow O
in O
acidic O
soil O
, O
with O
different O
specie O
in O
wet O
acid O
bog O
habitat O
( O
k. B-Plant
angustifolia I-Plant
, O
k. B-Plant
polifolia I-Plant
) O
and O
dry O
, O
sandy O
soil O
( O
k. B-Plant
ericoide I-Plant
, O
k. B-Plant
latifolia I-Plant
) O
. O
describe O
, O
a O
costly O
rarity O
, O
in O
-PRON- O
natural O
history O
of O
carolina O
, O
as O
chamaedaphne O
foliis O
tini O
, O
that O
be O
to O
say O
with O
leaf O
like O
the O
laurustinus B-Plant
the O
foliage O
be O
toxic O
if O
eat O
, O
with O
sheep O
be O
particularly O
prone O
to O
poisoning O
, O
hence O
the O
name O
lambkill B-Plant
use O
for O
some O
of O
the O
specie O
. O

other O
name O
for O
kalmia O
, O
particularly O
kalmia B-Plant
angustifolia I-Plant
, O
be O
sheep B-Plant
- I-Plant
laurel I-Plant
, O
lamb B-Plant
- I-Plant
kill I-Plant
, O
calf B-Plant
- I-Plant
kill I-Plant
, O
kill B-Plant
- I-Plant
kid I-Plant
, O
and O
sheep B-Plant
- I-Plant
poison I-Plant
, O
which O
may O
be O
write O
with O
or O
without O
the O
hyphen O
. O

have O
also O
be O
call O
spoonwood B-Plant
because O
kalm O
be O
tell O
by O
dutch O
settler O
of O
north O
america O
that O
native O
americans O
make O
spoon O
from O
the O
wood O
. O

impatien B-Plant
noli I-Plant
- I-Plant
tangere I-Plant
( O
touch B-Plant
- I-Plant
-PRON- I-Plant
- I-Plant
not I-Plant
balsam I-Plant
also O
call O
touch B-Plant
- I-Plant
-PRON- I-Plant
- I-Plant
not I-Plant
, O
yellow B-Plant
balsam I-Plant
, O
jewelwe B-Plant
, O
western B-Plant
touch I-Plant
- I-Plant
-PRON- I-Plant
- I-Plant
not I-Plant
or O
wild B-Plant
balsam I-Plant
. O

guthriea B-Plant
capensis I-Plant
be O
an O
acaulescent O
perennial O
herb O
endemic O
to O
south O
africa O
and O
occur O
in O
cool O
and O
damp O
site O
face O
south O
or O
east O
in O
the O
mountain O
of O
the O
cape O
province O
, O
lesotho O
and O
kwazulu O
- O
natal O
. O

this O
ground O
- O
hugging O
specie O
with O
a O
rhizome O
and O
fleshy O
root O
form O
a O
compact O
rosette O
of O
some O
20 O
- O
30 O
broadly O
elliptic O
or O
cordate O
discolorous O
leaf O
with O
crenate O
margin O
, O
measure O
about O
50 O
x O
75 O
mm O
, O
glossy O
above O
with O
deeply O
indented O
venation O
hide O
creamy O
- O
green O
flower O
which O
be O
solitary O
and O
stalk O
. O

guthriea O
belong O
to O
the O
family O
achariaceae O
, O
a O
family O
which O
now O
include O
various O
specie O
previously O
place O
in O
the O
flacourtiaceae O
, O
such O
as O
kiggelaria B-Plant
africana I-Plant
, O
rawsonia B-Plant
lucida I-Plant
and O
xylotheca B-Plant
kraussiana I-Plant
. O

several O
specie O
be O
grow O
in O
garden O
, O
especially O
b. B-Plant
frutescen I-Plant
. O

the O
genus O
include O
the O
important O
group O
of O
culinary O
herb O
: O
marjoram B-Plant
( O
origanum B-Plant
majorana I-Plant
) O
and O
oregano B-Plant
( O
origanum O
vulgare O
origanum O
species O
be O
use O
as O
food O
plant O
by O
the O
larvae O
of O
some O
lepidoptera O
specie O
, O
include O
coleophora O
albitarsella O
. O

be O
sometimes O
call O
cottonros O
or O
cudweed B-Plant
. O

the O
name O
cudweed B-Plant
come O
from O
the O
fact O
that O
-PRON- O
be O
once O
use O
to O
feed O
cow O
that O
have O
lose O
the O
ability O
to O
chew O
the O
cud O
. O

jensenia O
be O
a O
bryophyte O
plant O
genus O
in O
the O
liverwort B-Plant
family O
pallaviciniaceae O
. O

one O
of O
the O
specie O
, O
catopsis B-Plant
berteroniana I-Plant
, O
be O
think O
to O
be O
carnivorous O
. O

phlox B-Plant
hoodii I-Plant
, O
the O
spiny B-Plant
phlox I-Plant
or O
carpet B-Plant
phlox I-Plant
, O
be O
a O
species O
of O
phlox B-Plant
. O

be O
a O
plant O
of O
western O
north O
america O
, O
where O
-PRON- O
be O
a O
common O
flower O
in O
sagebrush B-Plant
country O
. O

gastrodia O
be O
a O
genus O
of O
achlorophyllous O
orchid B-Plant
with O
64 O
currently O
accept O
specie O
. O

gastrodia B-Plant
elata I-Plant
be O
a O
traditional O
chinese O
herb O
, O
tian O
ma O
( O
chinese O
: O
å¤©éº» O
) O
, O
and O
be O
commonly O
use O
in O
china O
to O
treat O
hypertension O
, O
improve O
circulation O
and O
resolve O
headache O
. O

anthoceros O
be O
a O
genus O
of O
hornwort B-Plant
in O
the O
family O
anthocerotaceae O
. O

name O
mean O
' O
flower O
horn O
' O
, O
and O
refer O
to O
the O
characteristic O
horn O
- O
shape O
sporophyte O
that O
all O
hornwort B-Plant
produce O
. O

rumex B-Plant
dentatus I-Plant
be O
a O
species O
of O
flower O
plant O
in O
the O
knotweed O
family O
know O
by O
the O
common O
name O
tooth B-Plant
dock I-Plant
and O
aegean O
dock O
. O

the O
group O
include O
many O
well O
- O
know O
desert O
and O
dry O
zone O
type O
such O
as O
the O
agave O
, O
yucca B-Plant
, O
and O
joshua B-Plant
tree I-Plant
. O

cryptocoryne B-Plant
beckettii I-Plant
( O
also O
know O
as O
beckett B-Plant
's I-Plant
water I-Plant
trumpet I-Plant
) O
be O
a O
plant O
specie O
belong O
to O
the O
aroid O
genus O
cryptocoryne O
. O

crataegus B-Plant
Ã— I-Plant
lavalleei O
, O
sometimes O
know O
as O
hybrid O
cockspurthorn B-Plant
or O
lavallÃ©e B-Plant
's I-Plant
hawthorn I-Plant
, O
be O
a O
hybrid O
that O
arise O
between O
cultivate O
specimen O
of O
two O
specie O
in O
the O
genus O
crataegus O
( O
hawthorn B-Plant
) O
. O

the O
female O
parent O
be O
c. B-Plant
mexicana I-Plant
( O
sometimes O
mistakenly O
call O
c. B-Plant
pubescen I-Plant
) O
, O
and O
the O
male O
parent O
be O
think O
to O
be O
c. B-Plant
calpodendron I-Plant
( O
which O
be O
sometimes O
mistakenly O
call O
c. O
crus O
- O
galli O
) O
's O
hawthorn B-Plant
, O
c. B-Plant
Ã— I-Plant
carrierei O
have O
the O
same O
parentage O
, O
and O
be O
therefore O
a O
synonym O
, O
i.e. O
there O
be O
minor O
difference O
between O
lavallÃ©e B-Plant
's I-Plant
hawthorn I-Plant
and O
carriÃ¨re B-Plant
's I-Plant
hawthorn I-Plant
, O
and O
the O
latter O
be O
consider O
a O
separate O
cultivar O
, O
which O
be O
formally O
write O
as O
crataegus O
' O
carrierei O
' O
. O

crataegus B-Plant
Ã— I-Plant
lavalleei O
be O
an O
ornamental O
small O
tree O
with O
glossy O
dark O
green O
unlob O
leaf O
that O
be O
use O
horticulturally O
. O

cedronella O
be O
a O
genus O
of O
flower O
plant O
in O
the O
mentheae O
tribe O
of O
family O
lamiaceae O
, O
comprise O
a O
single O
specie O
, O
cedronella B-Plant
canariensis I-Plant
, O
native O
to O
the O
canary O
islands O
, O
the O
azores O
, O
and O
madeira O
. O

common O
name O
include O
canary B-Plant
islands I-Plant
- I-Plant
balm I-Plant
, O
canary B-Plant
balm I-Plant
, O
and O
balm B-Plant
- I-Plant
of I-Plant
- I-Plant
gilead I-Plant
. O

the O
genus O
name O
be O
a O
diminutive O
of O
cedrus O
, O
though O
the O
only O
connection O
between O
this O
herb O
and O
the O
large O
conifer B-Plant
of O
cedrus O
be O
a O
vaguely O
similar O
resinous O
scent O
of O
the O
foliage O
. O

the O
genus O
platanthera O
belong O
to O
the O
subfamily O
orchidoideae O
of O
the O
family O
orchidaceae O
, O
and O
comprise O
about O
100 O
specie O
of O
orchid B-Plant
. O

the O
member O
of O
this O
genus O
, O
know O
as O
the O
butterfly B-Plant
orchid I-Plant
or O
fringed B-Plant
orchid I-Plant
, O
be O
previously O
include O
in O
the O
genus O
orchis O
, O
which O
be O
a O
close O
relative O
( O
along O
with O
the O
genus O
habenaria O
) O
. O

one O
specie O
, O
pitcairnia B-Plant
feliciana I-Plant
be O
find O
in O
tropical O
west O
africa O
and O
be O
the O
only O
member O
of O
the O
bromeliaceae O
family O
not O
native O
to O
the O
western O
hemisphere O
. O

marchantiopsida O
be O
one O
of O
three O
class O
within O
the O
liverwort B-Plant
phylum O
marchantiophyta O
. O

quercus B-Plant
garryana I-Plant
, O
the O
garry B-Plant
oak I-Plant
, O
oregon B-Plant
white I-Plant
oak I-Plant
, O
oregon B-Plant
oak I-Plant
, O
or O
hu'dshnam O
, O
from O
the O
traditional O
klamath O
language O
, O
be O
a O
tree O
specie O
with O
a O
range O
stretch O
from O
southern O
california O
to O
southwestern O
british O
columbia O
. O

the O
tree O
get O
one O
of O
name O
from O
nicholas O
garry O
, O
deputy O
governor O
of O
the O
hudson B-Plant
's O
bay O
company O
, O
1822â€“35 O
. O

alligator B-Plant
- I-Plant
flag I-Plant
be O
a O
common O
name O
for O
plant O
in O
this O
genus O
. O

drosophyllum O
( O
, O
rarely O
) O
be O
a O
genus O
of O
carnivorous O
plant O
contain O
the O
single O
specie O
drosophyllum B-Plant
lusitanicum I-Plant
( O
portuguese O
sundew B-Plant
or O
dewy O
pine B-Plant
) O
. O

drosophyllum B-Plant
lusitanicum I-Plant
bear O
bright O
- O
yellow O
flower O
, O
4 O
cm O
( O
1.6 O
in O
) O
in O
diameter O
, O
bear O
in O
group O
of O
3â€“15 O
between O
february O
and O
May O
the O
translucent O
seedpod O
bear O
3â€“10 O
opaque O
black O
, O
pear B-Plant
- O
shape O
seed O
, O
2.5 O
mm O
( O
98 O
in O
) O
in O
diameter O
. O

drosera B-Plant
paradoxa I-Plant
be O
a O
carnivorous O
plant O
in O
the O
genus O
drosera O
and O
be O
endemic O
to O
the O
northern O
territory O
and O
western O
australia O
. O

inflorescence O
be O
20â€“40 O
cm O
( O
8â€“16 O
in O
) O
long O
with O
pink O
or O
white O
flower O
be O
produce O
on O
-50 O
to O
70-flowered O
crowded O
raceme O
from O
july O
to O
september O
during O
the O
dry O
season O
. O

drosera B-Plant
paradoxa I-Plant
be O
find O
in O
skeletal O
sandy O
soil O
over O
sandstone O
in O
or O
along O
the O
bank O
of O
seasonally O
dry O
creek O
or O
in O
sandstone O
crack O
. O

drosera B-Plant
paradoxa I-Plant
be O
native O
to O
the O
west O
and O
north O
coast O
of O
the O
kimberley O
region O
inland O
to O
beverley O
springs O
, O
western O
australia O
and O
east O
to O
arnhem O
land O
and O
kakadu O
national O
park O
in O
the O
northern O
territory O
. O

be O
first O
describe O
by O
australian O
botanist O
allen O
lowrie O
in O
a O
1997 O
issue O
of O
nuytsia O
, O
the O
journal O
of O
the O
western O
australian O
herbarium O
. O

several O
trip O
into O
the O
field O
from O
1993 O
to O
1997 O
be O
require O
to O
reveal O
these O
different O
form O
to O
be O
only O
stage O
in O
this O
specie O
' O
perennial O
growth O
cycle O
from O
seedl O
to O
pincushion B-Plant
basal O
rosette O
to O
erect O
woody O
- O
stemmed O
speciman O
. O

be O
closely O
related O
to O
d. B-Plant
petiolaris I-Plant
, O
but O
differ O
from O
that O
specie O
most O
notably O
by O
-PRON- O
tall O
woody O
stem O
whereas O
d. B-Plant
petiolaris I-Plant
form O
clump O
of O
many O
basal O
rosette B-Plant
from O
a O
common O
perennial O
rootstock O
. O

illicium B-Plant
anisatum I-Plant
, O
with O
common O
name O
japanese B-Plant
star I-Plant
anise I-Plant
, O
aniseed O
tree O
, O
and O
sacred O
anise B-Plant
tree I-Plant
, O
know O
in O
japan O
as O
shikimi O
( O
be O
a O
tree O
closely O
related O
to O
the O
chinese B-Plant
star I-Plant
anise I-Plant
( O
illicium B-Plant
verum I-Plant
) O
. O

in  O
1917 O
and O
1918 O
with O
herbert O
carr O
, O
r O
a O
frazer O
, O
i O
a O
richards O
( O
and O
his O
spaniel O
sancho O
panza O
) O
, O
c O
f O
holland O
and O
others O
, O
she O
explored O
tryfan O
, O
lliwedd O
, O
the O
devil O
's O
kitchen O
, O
cwm O
idwal O
151 O
and O
was O
one O
of O
the O
first O
party O
up O
holly B-Plant
tree I-Plant
wall O
. O

the O
trees O
were O
the O
real O
enemy O
, O
old O
trees O
, O
young O
trees O
, O
rotten O
and O
burnt O
trees O
, O
douglas B-Plant
firs I-Plant
, O
jack O
pines B-Plant
, O
spruce B-Plant
, O
poplar B-Plant
and O
birch B-Plant
; O
the O
lower O
slopes O
between O
2700 O
and O
3000 O
metres O
are O
dominated O
by O
the O
yunnan B-Plant
pine I-Plant
pinus B-Plant
yunnanensis I-Plant
which O
is O
interspersed O
with O
hardwood O
trees O
such O
as O
poplar B-Plant
and O
lime B-Plant
as O
well O
as O
a O
very O
wide O
range O
of O
interesting O
shrubs O
. O

above O
the O
deciduous O
tree O
- O
line O
, O
pine B-Plant
forests O
compete O
with O
swashes O
of O
yellow B-Plant
azalea I-Plant
giving O
way O
to O
meadows O
bejewelled O
with O
alpine O
flowers O
swept O
by O
wave O
- O
tossed O
tracts O
of O
the O
white O
blossomed O
rhododendron B-Plant
caucasicum I-Plant
. O

wild B-Plant
jasmine I-Plant
( O
jasminum B-Plant
fruticans I-Plant
) O
and O
bar B-Plant
- I-Plant
berry I-Plant
( O
berberis B-Plant
vulgaris I-Plant
) O
bloom O
amidst O
the O
glossy O
evergreen O
foliage O
of O
straw B-Plant
- I-Plant
berry I-Plant
trees O
( O
arbutus O
unedd O
) O
and O
spanish B-Plant
laurel I-Plant
( O
laurus B-Plant
nobilis I-Plant
) O
, O
whilst O
the O
turpentine B-Plant
tree I-Plant
( O
pistacia B-Plant
terebinthus I-Plant
) O
, O
a O
close O
relative O
of O
the O
pistachio B-Plant
, O
spreads O
its O
leaves O
in O
the O
sunniest O
spots O
together O
with O
wild O
figs B-Plant
( O
ficus B-Plant
carica I-Plant
) O
, O
walnuts B-Plant
( O
juglans B-Plant
regia I-Plant
) O
and O
olives B-Plant
( O
olea B-Plant
europaea I-Plant
ssp. I-Plant
sylvestris I-Plant
) O
. O

its O
abun O
- O
dant O
forests O
, O
exploited O
by O
seafaring O
nations O
from O
the O
romans O
onwards O
, O
combine O
chestnut B-Plant
, O
oak B-Plant
, O
beech B-Plant
and O
, O
above O
all O
, O
the O
transcendental O
corsican B-Plant
pine I-Plant
, O
a O
monarch O
of O
european O
trees O
, O
which O
attains O
700 O
years O
of O
age O
and O
over O
50 O
m O
in O
height O
. O

from O
a O
distance O
the O
tree O
silhouettes O
could O
have O
been O
scots O
pines B-Plant
, O
but O
were O
actually O
evergreen O
beech B-Plant
nothofagus B-Plant
betuloides I-Plant
, O
intermingled O
with O
the O
autumn O
crimson O
and O
gold O
of O
deciduous O
southern B-Plant
beech I-Plant
nothofaguspumilla O
and O
antarctica O
. O

up O
in O
the O
fragile O
alpine O
zone O
, O
where O
even O
a O
small O
two O
- O
foot O
- O
diameter O
conifer B-Plant
( O
deodar B-Plant
or O
pine B-Plant
) O
will O
be O
some O
200 O
years O
old O
, O
we O
watched O
in O
horror O
as O
many O
of O
these O
trees O
were O
cut O
down O
merely O
to O
melt O
tar O
to O
put O
on O
the O
road O
. O

and O
, O
by O
the O
sacred O
lake O
of O
mabartsho O
, O
yellow O
tree O
paeonies O
, O
a O
variety O
of O
paeonia B-Plant
lutea I-Plant
. O

and O
on O
the O
walk O
- O
out O
next O
day O
there O
were O
fine O
tree B-Plant
ferns I-Plant
and O
bright O
blue O
iris B-Plant
decora I-Plant
. O

he O
pointed O
out O
a O
bequartodendron O
tree O
, O
enmeshed O
in O
a O
strangler O
fig B-Plant
which O
he O
had O
watched O
grow O
since O
he O
first O
came O
here O
in O
1962 O
. O

a O
pleasant O
scramble O
zigzags O
through O
boulders O
, O
prickly O
euphorbia O
and O
the O
surreal O
, O
fleshy O
kokerboom O
or O
' O
quiver O
' O
trees O
, O
whose O
pith B-Plant
was O
made O
into O
arrow O
quivers O
by O
the O
bushmen O
. O

13 O
we O
found O
a O
small O
group O
of O
mountain B-Plant
cabbage I-Plant
trees O
( O
cordyline B-Plant
indivisa I-Plant
) O
growing O
on O
the O
ridge O
above O
the O
tree O
line O
. O

not O
a O
sturdy O
english B-Plant
oak I-Plant
or O
anything O
of O
the O
kind O
, O
but O
a O
tree O
, O
a O
bush O
of O
a O
tree O
, O
of O
sorts O
. O

thick O
tangles O
of O
nothofagus B-Plant
antarctica I-Plant
had O
to O
be O
fought O
through O
, O
but O
on O
crossing O
the O
lapataia O
river O
we O
found O
guanaco O
trails O
, O
speeding O
progress O
through O
the O
forest O
and O
low O
tree O
scrub O
. O

run O
by O
mr O
conrad O
pinches O
, O
this O
school O
occupied O
one O
of O
the O
large O
terraced O
houses O
on O
the O
west O
side O
of O
the O
road O
running O
south O
from O
walnut B-Plant
tree O
walk O
. O

vol O
99 O
of O
the O
, O
4/(1994)contains O
an O
article O
by O
rosemary B-Plant
setting O
out O
the O
relationships O
and O
climbing O
achievements O
of O
her O
convoluted O
quaker O
family O
, O
together O
with O
a O
family O
tree O
. O

there O
was O
a O
small O
pink O
- O
headed O
onion B-Plant
here O
also O
( O
allium B-Plant
carolinianum I-Plant
) O
, O
collected O
by O
the O
kirghiz O
for O
food O
, O
as O
well O
as O
numerous O
aromatic O
herbs O
whose O
fragrance O
drifted O
across O
the O
slopes O
. O

herbs O
such O
as O
the O
beautiful O
george O
forrest O
's O
primrose B-Plant
primula B-Plant
forrestii I-Plant
with O
flowers O
of O
rich O
golden O
- O
yellow O
also O
flourish O
at O
this O
altitude O
, O
as O
does O
the O
rare O
and O
bizarre O
- O
looking O
slipper B-Plant
orchid I-Plant
cypripedium B-Plant
margaritaceum I-Plant
. O

the O
list O
of O
herbs O
which O
grow O
within O
this O
rich O
area O
of O
temperate O
forest O
is O
truly O
encyclopaedic O
, O
for O
here O
are O
to O
be O
found O
such O
treasures O
as O
primula B-Plant
bella I-Plant
, O
iris B-Plant
chrysographes I-Plant
, O
arisaema B-Plant
wilsonii I-Plant
and O
the O
yellow O
slipper B-Plant
orchid I-Plant
cypripedium B-Plant
flavum I-Plant
. O

until O
further O
work O
is O
done O
with O
the O
existing O
herbarium O
material O
it O
is O
doubtful O
whether O
we O
shall O
hear O
anything O
further O
of O
gentiana B-Plant
tilmanii I-Plant
. O

fruit O
and O
herbs O
that O
grew O
naturally O
in O
borrowdale O
rounded O
off O
an O
austere O
but O
healthy O
diet O
prepared O
over O
an O
open O
fire O
, O
a O
woodbine B-Plant
clasped O
between O
his O
toes B-Plant
to O
prevent O
ash O
falling O
into O
his O
food O
. O

and O
for O
its O
associations O
with O
the O
high O
places O
, O
the O
highland O
heather B-Plant
, O
so O
disagreeable O
to O
captain O
bun O
, O
was O
crowned O
by O
ruskin O
, O
with O
the O
blue O
gentian B-Plant
and O
the O
alpine B-Plant
rose I-Plant
, O
in O
uncontested O
queenliness O
, O
flowers O
wholly O
without O
similitude O
. O

even O
alpine O
flowers O
are O
at O
home O
here O
especially O
the O
' O
k'fcchenschelle O
' O
, O
the O
pasque B-Plant
flower I-Plant
( O
anemone O
pulsatilla O
) O
. O

a O
yellow O
starry O
- O
flowered O
clematis O
( O
c. B-Plant

hilariae I-Plant
) O
formed O
tumbled O
entanglements O
along O
field O
boundaries O
. O

along O
the O
rivers O
and O
streams O
there O
are O
the O
usual O
sedge B-Plant
pastures O
mixed O
with O
a O
few O
grasses O
but O
in O
the O
wet O
places O
, O
large O
drifts O
of O
deep O
blue O
primroses O
( O
primula B-Plant
macrophylla I-Plant
) O
and O
a O
small O
bright O
yellow O
buttercup B-Plant
( O
ranunculus B-Plant
pulchellus I-Plant
) O
were O
almost O
past O
flowering O
. O

most O
memorable O
was O
the O
carpet O
of O
crocus O
sieberi O
that O
grew O
so O
thick O
amidst O
the O
tussock B-Plant
grass I-Plant
of O
the O
upper O
pastures O
that O
it O
was O
impossible O
to O
avoid O
treading O
its O
flowers O
underfoot O
. O

in O
june O
the O
meadows O
at O
this O
altitude O
are O
alight O
with O
the O
colour O
of O
flowers O
- O
rhododendron B-Plant
adenogynutn I-Plant
occurs O
in O
flowing O
masses O
of O
pale O
pink O
, O
the O
yellow B-Plant
bells I-Plant
of O
lilium O
lopophorum O
stud O
the O
slopes O
in O
association O
with O
the O
purple O
lloydia B-Plant
tibetica I-Plant
var. I-Plant
purpurescens I-Plant
( O
an O
asian O
counterpart O
of O
the O
snowdon O
lily B-Plant
) O
and O
the O
golden O
meconopsis B-Plant
integrifolia I-Plant
. O

on O
the O
cliffs O
cling O
cushions O
of O
androsace B-Plant
delavayi I-Plant
and O
the O
almost O
impossibly O
- O
named O
solmslaubachia B-Plant
pulcherrima I-Plant
, O
one O
of O
forrest O
's O
favourite O
alpines O
with O
cress B-Plant
- O
like O
ice O
- O
blue O
flowers O
. O

best O
of O
all O
is O
the O
exquisite O
dwarf O
alpine O
' O
blue B-Plant
poppy I-Plant
' O
meconopsis B-Plant
delavayi I-Plant
which O
kingdon O
- O
ward O
described O
as O
' O
a O
shimmering O
bluish O
- O
violet B-Plant
flower O
with O
the O
texture O
of O
japanese O
silk O
' O
. O

higher O
still O
in O
the O
north O
- O
facing O
base O
- O
rich O
wetter O
flushes O
the O
seemingly O
uncultivatable O
primula B-Plant
dryadifolia I-Plant
shows O
its O
mauve O
- O
pink O
flowers O
against O
broad O
prostrate O
mats O
of O
foliage O
( O
25 O
cm O
across O
) O
, O
accompanied O
by O
three O
' O
sisters O
' O
of O
the O
same O
genus O
, O
primula B-Plant
pinnatifida I-Plant
, O
p O
secundiflora O
and O
p O
pseudo O
- O
sikkimensis O
. O

while O
we O
were O
on O
rajrambha O
the O
tiny O
blades O
of O
iris B-Plant
kumaonensis I-Plant
had O
suddenly O
sprouted O
purple O
flowers O
, O
streaked O
and O
mottled O
like O
the O
skin O
of O
exotic O
reptiles O
. O

) O
, O
towering O
white O
asphodels O
( O
asphodelus B-Plant
albus I-Plant
) O
( O
plate O
63 O
) O
and O
pyrenean B-Plant
lilies I-Plant
( O
lilium B-Plant
pyrenaicum I-Plant
) O
decorate O
these O
meadows O
, O
whilst O
the O
montane O
grasslands O
are O
renowned O
for O
their O
pasque B-Plant
- I-Plant
flowers I-Plant
( O
pulsatilla B-Plant
rubra I-Plant
, O
p. B-Plant
alpina I-Plant
( O
plate O
66 O
) O
and O
p. B-Plant
vernalis I-Plant
) O
, O
anemones B-Plant
( O
anemone B-Plant
pavoniana I-Plant
) O
, O
dog B-Plant
's I-Plant
violets I-Plant
( O
erythronium O
dens O
- O
can O
is O
) O
and O
pyrenean B-Plant
fritillaries I-Plant
( O
fritillaria B-Plant
pyrenaica I-Plant
) O
. O